[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Precision Medical, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":396},{"warningLetters":4,"total":395},[5,30,52,71,92,111,130,151,167,183,202,223,246,263,280,299,319,338,356,374],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},3235,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-26T04:00:00Z\">07\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021\">Lexion Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick Spearman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lexion Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Atwater Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pspearman@lexionmedical.com\"> pspearman@lexionmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 26, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Patrick Spearman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&amp;feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AP 50\u002F30 Insufflator and Insuflow Port\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\u003C\u002Fp>\n\n\u003Cp>For example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\u003C\u002Fp>\n\n\u003Cp>• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\u003Cbr>\n “Less hypothermia”\u003Cbr>\n “Less peritoneal damage”\u003Cbr>\n “Less postoperative pain”\u003Cbr>\n “Decreased amount of pain medication”\u003Cbr>\n “Shortened recovery room stay”\u003Cbr>\n “Less tissue dessication”\u003Cbr>\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\u003C\u002Fp>\n\n\u003Cp>There are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pneuview XE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\u003C\u002Fp>\n\n\u003Cp>• “Eliminate \u003Cem>all\u003C\u002Fem> plume, gases, and particles” [emphasis added]\u003Cbr>\n• “…eliminating \u003Cem>all\u003C\u002Fem> harmful contaminants associated with combustion, including viral particles” [emphasis added]\u003Cbr>\n• “actively evacuates and removes \u003Cem>all \u003C\u002Fem>smoke plume including hazardous gas” [emphasis added]\u003Cbr>\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\u003C\u002Fp>\n\n\u003Cp>The cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\u003Cbr>\n\u003Cbr>\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\u003C\u002Fp>\n\n\u003Cp>• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\u003Cbr>\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\u003Cbr>\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\u003C\u002Fp>\n\n\u003Cp>• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\u003Cbr>\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\u003Cbr>\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\u003Cbr>\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\u003Cbr>\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\u003Cbr>\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\u003C\u002Fp>\n\n\u003Cp>Taken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>In combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC\u003Cbr>\nShelly Amann, Owner\u003Cbr>\nLexion Medical LLC\u003Cbr>\n545 Atwater Circle\u003Cbr>\nSaint Paul, MN 55103\u003Cbr>\nsamann@lexionmedical.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. \u003Cem>J Robot Surg\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick Spearman\n\nRecipient Title\n\nOwner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nUnited States\n\npspearman@lexionmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJuly 26, 2021\n\nRE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Patrick Spearman:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nAP 50\u002F30 Insufflator and Insuflow Port\n\nThe AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\n\nFor example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\n\n• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\n\n “Less hypothermia”\n\n “Less peritoneal damage”\n\n “Less postoperative pain”\n\n “Decreased amount of pain medication”\n\n “Shortened recovery room stay”\n\n “Less tissue dessication”\n\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\n\nThere are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\n\nPneuview XE\n\nThe Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\n\n• “Eliminate all plume, gases, and particles” [emphasis added]\n\n• “…eliminating all harmful contaminants associated with combustion, including viral particles” [emphasis added]\n\n• “actively evacuates and removes all smoke plume including hazardous gas” [emphasis added]\n\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\n\nThe cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\n\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\n\n• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\n\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”2 (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\n\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\n\nWe are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\n\nAdditionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-193 in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\n\n• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\n\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\n\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\n\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\n\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\n\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\n\nTaken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\n\nIn combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nNote, there are two response time frames specified. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\n\nYour firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\n\nPlease refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\n\nFinally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC\n\nShelly Amann, Owner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nsamann@lexionmedical.com\n\n______________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. J Robot Surg.\n\n3 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n4 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Lexion Medical LLC","lexion-medical-llc-613588-07262021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021","2026-10-26T08:09:14.12601+00:00","Warning Letter","Issued","2021-08-03","613588","Medical Devices","Patrick Spearman","2026-08-20T02:44:07.37+00:00","2021-07-26",{"id":31,"raw":32,"subject":36,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":45,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":48,"issuing_office":11,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},2964,[33,34,35,11,36,13,37,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-16T05:00:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-11162021\">Global Medical Production Co Ltd\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-05142026\">\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeff Dai General\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager &amp; Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Medical Production Co Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 4 Building, No.3288\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Zhongshan Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xiuzhou Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiaxing Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>314031\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 16, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Dai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Jiaxing, China on July 15, 2021 through July 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received two responses from you, dated August 19, 2021 and September 20, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not established Design Control procedures related to its private label manufactured medical devices intended for the US market to include Class II Sterile and Non-Sterile Electrosurgical Scissors, Class II Sterile Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles. Additionally, your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities for these medical devices. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would conduct training on 21 CFR 820.30 Design Control and Design Control Procedure, and retrospectively establish Design History Files for all products. The response also stated that your firm would provide training records, design history files for all of its products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be any assessment to determine the impact of the lack of design control activities for devices that were already distributed. Additionally, your firm has not provided documentation or evidence of implementation of a corrective action plan. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm’s Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018; has no requirement for: the evaluation and disposition of nonconforming products, which should include procedures for determination of the need for an investigation and notification of the person or organizations responsible for the nonconformance. Additionally, during the inspection of your firm’s list of 2019-2021 nonconforming products, there was no documentation or evidence that your firm had conducted a determination of the need for an investigation or notification of the persons and organizations responsible for the nonconformance.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would revise the Nonconforming Product Procedure Document Number 28301 to add missing information for the evaluation and disposition of nonconforming products, which should include a determination of the need for an investigation and notification of the person or organization responsible for the nonconformance. Your firm also stated that it would retrospectively review the history of Nonconforming product and determine the need for an investigation as well as notification of the persons and organizations responsible for the nonconformance and disposition of the nonconforming product. Additionally, effectiveness checks would be initiated after all corrective and preventive actions were taken.&nbsp; However, the response did not indicate that there would be an assessment to determine if the lack of disposition requirements led to a release of nonconforming product and how that risk will be addressed. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example, your firm was not able to provide Performance Qualification (PQ) objective data and evidence or results of the PQ activities. Your firm stated that it does not have the results of the PQ conducted for its heat-sealing process validation activities, which is used in manufacturing processes of medical devices exported and intended for the US market. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would execute a new Performance Qualification and would also assess all other processes and Performance Qualifications for objective data and results. A new Performance Qualification would be executed where data or results were not found. Your firm stated it would provide the agency with PQ data, its PQ summary Report, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records. However, the response did not indicate that there would be any corrective actions to ensure that the firm maintains such records in the future. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>4. Failure to conduct periodic inspections in accordance with established procedures to ensure adherence to applicable equipment maintenance schedules, as required by 21 CFR 820.70(g)(1).\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not established a maintenance schedule for your Production Controlled Room Air Handling HEPA Filters and Water Purifier, Equipment No. 08, used in the ultrasonic cleaning of components of your firm’s private label manufactured medical devices intended for the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would establish a maintenance schedule for the Production Controlled Room Air Handling HEPA Filters and Water Purifier Equipment No. 08. Your firm stated that it would provide training for new procedure and provide the agency with records of the retrospective schedule, maintenance schedules, effectiveness check reports and a recommendation for additional actions or closure. However, the response did not indicate that there would be an assessment to determine the impact from the lack of maintenance schedule on previously released product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>5. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\u003C\u002Fp>\n\n\u003Cp>For example, your firm had product in the warehouse that was labeled as “sterile” and was intended for the U.S. market. However, the product should have been identified as \"Non-Sterile” to indicate its non-processed and non-sterile status to ensure only medical devices that have undergone the sterilization process are accepted and distributed to the US market. Your firm stated that it has no process or requirement to ensure “Non-Sterile” product is conspicuously labeled to indicate its non-processed, non-sterile status from sterile product. Your firm does not follow its Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018. Medical device components and finished medical devices were not properly identified to ensure that only product which has passed the required acceptance activities are distributed or used.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm would revise Document 27502, Product Identification and Traceability to add method for identifying the status of product. Your firm also plans to establish a new procedure to address placing the sterile indicator label on the product package to identify product before and after the process of sterilization by December 15, 2021. Your firm will establish a new procedure for physically separating product and identifying each location with product status. Document 28301, section 6.3.2.1 and 6.3.2.2, will be revised to remove sections for green and red labels and replace with a label that has a section to indicate accept or reject status. The Identification Procedure will be revised to include physical storage area status.\u003C\u002Fp>\n\n\u003Cp>A new procedure will be established to identify scrap product with \"not for human use label.\" Your firm will identify storage areas in the facility with proper identification and segregate manufacturing and storage areas to prevent possible mix-ups. Products will be quarantined in the unmarked storage room and assign a Non-Conformance Number to the product, disposition of the product, and identity of the product. Additionally, upon completion of all corrective and preventive actions, your firm will conduct an effectiveness check. Based on results of the effectiveness check, GMP may recommend additional actions or closure of this observation. However, the response did not indicate that there would be an assessment to determine if the lack of adequate identification led to the release of unsterilized product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003Cbr>\n\u003Cbr>\nFor example, your firm’s Customer Complaint Control Procedure, Doc No. 28502, Ver. 3, and dated February 01, 2018, has no requirement to ensure your firm is receiving complaints from its sole distributor that is marketing and selling its private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its sole US private label distributor requiring them provide your firm with complaints to ensure that it reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and are evaluated to determine whether the complaint represents an event, which is required to be reported to the USFDA under 21 CFR Part 803 - Medical Device Reporting (MDR).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm stated that it executed a Quality Agreement with its US Distributor that requires the distributor to provide your firm with complaints and provided the agency with a copy of this agreement. Your firm’s response stated that it would revise its Customer Complaint Procedure and retrospectively establish a Customer Complaint Log to record complaint activities. Additionally, the response stated that it would review and evaluate all complaints in a uniform and timely manner to determine whether an investigation is necessary. The response also stated that it would provide the agency with its revised procedure, customer complaint logs, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be a retrospective assessment to determine if the complaints previously received by the initial importer present quality problems that were previously unknown. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>7. Failure to maintain device master records as required by 820.181.\u003C\u002Fp>\n\n\u003Cp>For example, your firm has not maintained Device Master Records related to your firm's private label manufactured medical devices for the US market to include, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm stated it would conduct training to 21 CFR 820.181 its Quality Manual Procedure Document Number 24101, and retrospectively establish a Device Master Records for all products. The response also stated that it would provide Device Master Records for all products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>8. Failure to maintain device history records as required by 820.184.\u003C\u002Fp>\n\n\u003Cp>For example, your firm was not able to provide device history records for private label manufactured medical devices intended and exported to the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm’s response stated that it had a device history record for all of its products but that it had not been translated during the inspection. Your firm stated that it would provide a device history records for each product that it would provide recommendations for additional actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C.§ 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain and implement written a Medical Device Reporting (MDR) procedure, as required by 21 CFR 803.17. For example, during the inspection, your firm acknowledged that it does not have an MDR procedure. This is a repeat violation from the previous inspection in April 2015.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. The response noted the following corrective actions: Implement a Medical Device Procedure compliant with 21 CFR 803.17 by September 30, 2021, perform a retrospectively review of all complaints from 2018 to present to evaluate for MDR reportability and submit all the identified MDRs by December 1, 2021 and Perform effectiveness check and report to the FDA within 90 days of completing all corrective and preventative actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 620544 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT 4: Office of Office of Surgery and\u003Cbr>\nInfection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological\u003Cbr>\nHealth\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMike Athey\u003Cbr>\n2526 Old Lake Mary Road\u003Cbr>\nSanford, FL 32773\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeff Dai General\n\nRecipient Title\n\nManager & Co-Owner\n\nGlobal Medical Production Co Ltd\n\nNo. 4 Building, No.3288\n\nWest Zhongshan Road\n\nXiuzhou Qu\n\nJiaxing Shi\n\nZhejiang Sheng, 314031\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nNovember 16, 2021\n\nDear Mr. Dai:\n\nDuring an inspection of your firm located in Jiaxing, China on July 15, 2021 through July 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received two responses from you, dated August 19, 2021 and September 20, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nFor example, your firm has not established Design Control procedures related to its private label manufactured medical devices intended for the US market to include Class II Sterile and Non-Sterile Electrosurgical Scissors, Class II Sterile Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles. Additionally, your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities for these medical devices. This is a repeat violation from the previous inspection in April 2015.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would conduct training on 21 CFR 820.30 Design Control and Design Control Procedure, and retrospectively establish Design History Files for all products. The response also stated that your firm would provide training records, design history files for all of its products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be any assessment to determine the impact of the lack of design control activities for devices that were already distributed. Additionally, your firm has not provided documentation or evidence of implementation of a corrective action plan. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\n\nFor example, your firm’s Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018; has no requirement for: the evaluation and disposition of nonconforming products, which should include procedures for determination of the need for an investigation and notification of the person or organizations responsible for the nonconformance. Additionally, during the inspection of your firm’s list of 2019-2021 nonconforming products, there was no documentation or evidence that your firm had conducted a determination of the need for an investigation or notification of the persons and organizations responsible for the nonconformance.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would revise the Nonconforming Product Procedure Document Number 28301 to add missing information for the evaluation and disposition of nonconforming products, which should include a determination of the need for an investigation and notification of the person or organization responsible for the nonconformance. Your firm also stated that it would retrospectively review the history of Nonconforming product and determine the need for an investigation as well as notification of the persons and organizations responsible for the nonconformance and disposition of the nonconforming product. Additionally, effectiveness checks would be initiated after all corrective and preventive actions were taken. However, the response did not indicate that there would be an assessment to determine if the lack of disposition requirements led to a release of nonconforming product and how that risk will be addressed. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\n\nFor example, your firm was not able to provide Performance Qualification (PQ) objective data and evidence or results of the PQ activities. Your firm stated that it does not have the results of the PQ conducted for its heat-sealing process validation activities, which is used in manufacturing processes of medical devices exported and intended for the US market. This is a repeat violation from the previous inspection in April 2015.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would execute a new Performance Qualification and would also assess all other processes and Performance Qualifications for objective data and results. A new Performance Qualification would be executed where data or results were not found. Your firm stated it would provide the agency with PQ data, its PQ summary Report, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records. However, the response did not indicate that there would be any corrective actions to ensure that the firm maintains such records in the future. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions as they are still ongoing. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\n4. Failure to conduct periodic inspections in accordance with established procedures to ensure adherence to applicable equipment maintenance schedules, as required by 21 CFR 820.70(g)(1).\n\nFor example, your firm has not established a maintenance schedule for your Production Controlled Room Air Handling HEPA Filters and Water Purifier, Equipment No. 08, used in the ultrasonic cleaning of components of your firm’s private label manufactured medical devices intended for the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers, and Class II Sterile Veress Pneumoperitoneum Needles.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it would establish a maintenance schedule for the Production Controlled Room Air Handling HEPA Filters and Water Purifier Equipment No. 08. Your firm stated that it would provide training for new procedure and provide the agency with records of the retrospective schedule, maintenance schedules, effectiveness check reports and a recommendation for additional actions or closure. However, the response did not indicate that there would be an assessment to determine the impact from the lack of maintenance schedule on previously released product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\n5. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\n\nFor example, your firm had product in the warehouse that was labeled as “sterile” and was intended for the U.S. market. However, the product should have been identified as \"Non-Sterile” to indicate its non-processed and non-sterile status to ensure only medical devices that have undergone the sterilization process are accepted and distributed to the US market. Your firm stated that it has no process or requirement to ensure “Non-Sterile” product is conspicuously labeled to indicate its non-processed, non-sterile status from sterile product. Your firm does not follow its Nonconforming Product Control Procedure, Doc No. 28301, Ver. 2 and dated February 01, 2018. Medical device components and finished medical devices were not properly identified to ensure that only product which has passed the required acceptance activities are distributed or used.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm would revise Document 27502, Product Identification and Traceability to add method for identifying the status of product. Your firm also plans to establish a new procedure to address placing the sterile indicator label on the product package to identify product before and after the process of sterilization by December 15, 2021. Your firm will establish a new procedure for physically separating product and identifying each location with product status. Document 28301, section 6.3.2.1 and 6.3.2.2, will be revised to remove sections for green and red labels and replace with a label that has a section to indicate accept or reject status. The Identification Procedure will be revised to include physical storage area status.\n\nA new procedure will be established to identify scrap product with \"not for human use label.\" Your firm will identify storage areas in the facility with proper identification and segregate manufacturing and storage areas to prevent possible mix-ups. Products will be quarantined in the unmarked storage room and assign a Non-Conformance Number to the product, disposition of the product, and identity of the product. Additionally, upon completion of all corrective and preventive actions, your firm will conduct an effectiveness check. Based on results of the effectiveness check, GMP may recommend additional actions or closure of this observation. However, the response did not indicate that there would be an assessment to determine if the lack of adequate identification led to the release of unsterilized product. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nFor example, your firm’s Customer Complaint Control Procedure, Doc No. 28502, Ver. 3, and dated February 01, 2018, has no requirement to ensure your firm is receiving complaints from its sole distributor that is marketing and selling its private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its sole US private label distributor requiring them provide your firm with complaints to ensure that it reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and are evaluated to determine whether the complaint represents an event, which is required to be reported to the USFDA under 21 CFR Part 803 - Medical Device Reporting (MDR).\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm stated that it executed a Quality Agreement with its US Distributor that requires the distributor to provide your firm with complaints and provided the agency with a copy of this agreement. Your firm’s response stated that it would revise its Customer Complaint Procedure and retrospectively establish a Customer Complaint Log to record complaint activities. Additionally, the response stated that it would review and evaluate all complaints in a uniform and timely manner to determine whether an investigation is necessary. The response also stated that it would provide the agency with its revised procedure, customer complaint logs, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, the response did not indicate that there would be a retrospective assessment to determine if the complaints previously received by the initial importer present quality problems that were previously unknown. Additionally, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n7. Failure to maintain device master records as required by 820.181.\n\nFor example, your firm has not maintained Device Master Records related to your firm's private label manufactured medical devices for the US market to include, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm stated it would conduct training to 21 CFR 820.181 its Quality Manual Procedure Document Number 24101, and retrospectively establish a Device Master Records for all products. The response also stated that it would provide Device Master Records for all products, effectiveness check reports, recommendations for additional actions or closure if applicable, and training records related to these corrective actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\n8. Failure to maintain device history records as required by 820.184.\n\nFor example, your firm was not able to provide device history records for private label manufactured medical devices intended and exported to the US market, to include Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Scissors, Class II Sterile Disposable and Non-Sterile Reusable Electrosurgical Graspers and Class II Sterile Veress Pneumoperitoneum Needles.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm’s response stated that it had a device history record for all of its products but that it had not been translated during the inspection. Your firm stated that it would provide a device history records for each product that it would provide recommendations for additional actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. This information is needed to assess whether these correction actions were completed.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C.§ 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain and implement written a Medical Device Reporting (MDR) procedure, as required by 21 CFR 803.17. For example, during the inspection, your firm acknowledged that it does not have an MDR procedure. This is a repeat violation from the previous inspection in April 2015.\n\nThe adequacy of your firm’s response cannot be determined at this time. The response noted the following corrective actions: Implement a Medical Device Procedure compliant with 21 CFR 803.17 by September 30, 2021, perform a retrospectively review of all complaints from 2018 to present to evaluate for MDR reportability and submit all the identified MDRs by December 1, 2021 and Perform effectiveness check and report to the FDA within 90 days of completing all corrective and preventative actions. However, your firm has not provided documentation or evidence of implementation of the corrective actions. The FDA cannot make an assessment with respect to adequacy without such documentation. Please provide evidence of the corrective actions that you outlined in your responses. We request this information to assess whether these correction actions were completed.\n\nGiven the serious nature of the violations of the Act, Sterile and Non-Sterile Electrosurgical Scissors, Sterile Electrosurgical Graspers, and Sterile Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 620544 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT 4: Office of Office of Surgery and\n\nInfection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological\n\nHealth\n\nCC:\n\nMike Athey\n\n2526 Old Lake Mary Road\n\nSanford, FL 32773","Global Medical Production Co Ltd","global-medical-production-co-ltd-620544-11162021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-medical-production-co-ltd-620544-11162021","2026-10-26T08:08:46.668846+00:00","Closed Out","2021-12-21","620544","2026-05-18","Jeff Dai General","2026-08-20T02:18:38.641+00:00","2021-11-16",{"id":53,"raw":54,"subject":36,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":67,"body_fetched_at":68,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":70,"medical_device_id":19,"response_letter_date":19},1097,[55,56,57,11,36,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:00:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-09T05:00:00Z\">12\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024\">Phillips Precision, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeanne M. Phillips\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Phillips Precision, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7 Paul Kohner Pl\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmwood Park\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07407\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 697119\u003C\u002Fp>\u003Cp>December 9, 2024\u003C\u002Fp>\u003Cp>Dear Ms. Jeanne M. Phillips:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes. For example:\u003C\u002Fp>\u003Cp>A. Cleaning validations conducted for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” used to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean orthopedic implants and instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\u003C\u002Fp>\u003Cp>1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge \u003Cstrong>(b)(4)\u003C\u002Fstrong> as all loads were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong>; system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality above \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002F cm; clean time below \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes; and load weight above \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes as well as document the degassing time during OQ.\u003C\u002Fp>\u003Cp>In addition, you executed work orders during OQ without the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\u003C\u002Fp>\u003Cp>Furthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\u003C\u002Fp>\u003Cp>iii. You failed to define or document the load configuration for work orders 65926 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 64205 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 63988 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65917 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65921 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>75 devices), and 65791 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> which is allowed in section 5.2.4.2.6 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101881) enclosed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151) placed on top of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, neither of which were evaluated during OQ.\u003C\u002Fp>\u003Cp>2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. As specified in section 5.2.2 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality of the rinse tank is below (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) during normal operation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner. However, you failed to conduct PQ under normal operating conditions for system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality in that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> runs were run at ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm while the remaining cycles were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\u003C\u002Fp>\u003Cp>ii. You failed to utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, assembly, machine, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, these processes were not represented in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized during your PQ and your firm did not document justification for the equivalency of those \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> through objective evidence.\u003C\u002Fp>\u003Cp>3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, per section 10.4 of the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable \u003Cstrong>(b)(4)\u003C\u002Fstrong> states @ \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>***.” However, you assigned a severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4) \u003C\u002Fstrong>instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\u003C\u002Fp>\u003Cp>1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe devices which had already been cleaned on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fp>\u003Cp>2. The “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> during manufacturing) or documented justification for why validation of such devices was not necessary.\u003C\u002Fp>\u003Cp>C. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. For example:\u003C\u002Fp>\u003Cp>1. Your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested per lot for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively and the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units tested for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per lot would have required testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples per lot for each test.\u003C\u002Fp>\u003Cp>2. Your “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, cytotoxicity testing was only conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot and endotoxicity and particulate testing was conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> would have required a sufficient number of samples to be able to test a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples each for endotoxins, cytotoxicity, and particulates for a lot size between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the OQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong>; removal of any adhesives; load configurations; comingling; multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of actual products during OQ.\u003C\u002Fp>\u003Cp>With regards to PQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you dispute that \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity of the rinse tank was not conducted at nominal; however, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle was not done under normal operating conditions. You plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no corrective action identified to run system \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity under normal operating conditions (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) and define the optimal degassing time.\u003C\u002Fp>\u003Cp>With regards to the PFMEA for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you intend to review and update the existing PFMEA as needed; contact \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\u003C\u002Fp>\u003Cp>With regards to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to “amend” the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\u003C\u002Fp>\u003Cp>With regards to process validation for additional post-production cleaning processes, you state that the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and (medical grade) \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\u003C\u002Fp>\u003Cp>With regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and amendment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation will utilize a statistically valid sampling plan based on documented rationale.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\u003C\u002Fp>\u003Cp>A. You failed to implement section 5.2.4.2.5 which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101395) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 99014) in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> load.\u003C\u002Fp>\u003Cp>B. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: \u003Cstrong>(b)(4)\u003C\u002Fstrong> release instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98145) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151), which appeared be stacked in 3 layers. In addition, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" manual specifically states that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that challenges comingling will address the original purpose which was to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as noted in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. You have not defined and documented procedures to monitor and control the following parameters for the validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers:\u003C\u002Fp>\u003Cp>1. \u003Cu>Weight of the Load \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu>:\u003C\u002Fu> There is no procedure to ensure that the load \u003Cstrong>(b)(4)\u003C\u002Fstrong> weight is below \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>2. \u003Cu>Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks:\u003C\u002Fu> There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>3. \u003Cu>Concentration of the Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>4. \u003Cu>Time for Degassing of Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, which operates at \u003Cstrong>(b)(4)\u003C\u002Fstrong>kHz, is degassed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>B. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ to \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and documentation of the temperature on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (\u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the loads run on your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” were performed at out of specification temperatures. For example, your employees operated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner at temperatures lower than the minimum specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> orthopedic devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> surgical instruments).\u003C\u002Fp>\u003Cp>C. You have not established a procedure for the monitoring and control of temperature and time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Section 6.2 of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***\u003Cstrong>(b)(4)\u003C\u002Fstrong> is pre-heated***between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> F for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to application.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”; update the frequency as needed; and revise the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\u003C\u002Fp>\u003Cp>With regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning action only begins to deteriorate when temperatures go above certain limits (typically \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\u003C\u002Fp>\u003Cp>You also plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of parameters for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to review the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation and establish the applicable monitoring and control and amend the \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure to these said controls.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\u003C\u002Fp>\u003Cp>1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for \u003Cstrong>(b)(4)\u003C\u002Fstrong> blades received with metal debris, leftover burrs, and residue corresponding to \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), the corrective actions included (1) increasing clean time to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes for your in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning machines; (2) verifying use of the custom \u003Cstrong>(b)(4)\u003C\u002Fstrong> fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\u003C\u002Fp>\u003Cp>2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, may have affected other devices with similar geometries which also use the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines to remove residue and metal shards.\u003C\u002Fp>\u003Cp>3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>” on at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\u003C\u002Fp>\u003Cp>B. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Rejection % (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Occurrence (Score \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and Detectability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). A combined score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Almost Certain” while a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\u003C\u002Fp>\u003Cp>2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\u003C\u002Fp>\u003Cp>3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across \u003Cstrong>(b)(4)\u003C\u002Fstrong> unique part numbers.\u003C\u002Fp>\u003Cp>4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\u003C\u002Fp>\u003Cp>With regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples \u003Cstrong>(b)(4)\u003C\u002Fstrong> orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for \u003Cstrong>(b)(4)\u003C\u002Fstrong> associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\u003C\u002Fp>\u003Cp>With regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> not lowest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\u003C\u002Fp>\u003Cp>With regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\u003C\u002Fp>\u003Cp>A. \u003Cu>Internal Nonconformances, found during manufacturing and inspections (excluding \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections\u003C\u002Fu> – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\u003C\u002Fp>\u003Cp>B. \u003Cu>Internal nonconformances, only found during \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections conducted during manufacturing\u003C\u002Fu> – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal \u003Cstrong>(b)(4)\u003C\u002Fstrong> Scrap Log” and then discards the part along with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Acceptance Number Sampling Plan Fifth Edition” which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling. For example:\u003C\u002Fp>\u003Cp>A. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your personnel only used your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the critical diameter feature \u003Cstrong>(b)(4)\u003C\u002Fstrong> times (to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured \u003Cstrong>(b)(4)\u003C\u002Fstrong> times at \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the inspection plan was specified to follow the Acceptable Quality Limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (AQL \u003Cstrong>(b)(4)\u003C\u002Fstrong>) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices being returned and scrapped due to diameters exceeding the specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> +\u002F- \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. On 5\u002F17\u002F24, our investigator observed employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> operate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for machining of the metal locking date ring (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) under WO # 102106. Your operator explained that every \u003Cstrong>(b)(4)\u003C\u002Fstrong> piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. Your procedure to define and document the schedule for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowl and filter gauge pressure of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is inadequate. The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual requires drainage and monitoring of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> volume on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changed if it reaches \u003Cstrong>(b)(4)\u003C\u002Fstrong> PSI, there is no requirement to check the filter gauge pressure under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” section of your maintenance log (or elsewhere).\u003C\u002Fp>\u003Cp>B. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to review the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeanne M. Phillips\n\nRecipient Title\n\nOwner and CEO\n\nPhillips Precision, Inc.\n\n7 Paul Kohner Pl\n\nElmwood Park, NJ 07407\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 697119\nDecember 9, 2024\nDear Ms. Jeanne M. Phillips:\nDuring an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) and (b)(4) processes. For example:\nA. Cleaning validations conducted for the “(b)(4)” used to (b)(4) clean orthopedic implants and instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\n1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\ni. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “(b)(4)” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\nii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge (b)(4) as all loads were run at (b)(4); system (b)(4) quality above (b)(4) microsiemens\u002F cm; clean time below (b)(4) minutes; and load weight above (b)(4) pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under (b)(4) minutes as well as document the degassing time during OQ.\nIn addition, you executed work orders during OQ without the (b)(4) manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in (b)(4) out of (b)(4) work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\nFurthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\niii. You failed to define or document the load configuration for work orders 65926 ((b)(4) devices), 64205 ((b)(4) devices), 63988 ((b)(4) devices), 65917 ((b)(4) devices), 65921 ((b)(4)75 devices), and 65791 ((b)(4) devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple (b)(4). In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of (b)(4) which is allowed in section 5.2.4.2.6 of your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and (b)(4). On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # (b)(4); WO 101881) enclosed in a (b)(4) and the (b)(4) instrument (Part # (b)(4); WO 98151) placed on top of a (b)(4), neither of which were evaluated during OQ.\n2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\ni. As specified in section 5.2.2 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system (b)(4) quality of the rinse tank is below (≤ (b)(4) microsiemens\u002Fcm) during normal operation of your (b)(4) cleaner. However, you failed to conduct PQ under normal operating conditions for system (b)(4) quality in that only (b)(4) out of (b)(4) runs were run at ≤ (b)(4) microsiemens\u002Fcm while the remaining cycles were run at (b)(4) and (b)(4) microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\nii. You failed to utilize (b)(4) and (b)(4) which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # (b)(4)) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as (b)(4), assembly, machine, and (b)(4); however, these processes were not represented in the (b)(4) and (b)(4) utilized during your PQ and your firm did not document justification for the equivalency of those (b)(4) and (b)(4) through objective evidence.\n3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of (b)(4) through (b)(4). For example, per section 10.4 of the “Final (b)(4) Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “(b)(4)”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable (b)(4) states @ (b)(4), (b)(4), and (b)(4)***.” However, you assigned a severity of (b)(4) ((b)(4)) out of (b)(4) for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for (b)(4) out of (b)(4) of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); and (b)(4) instruments for Customer (b)(4).\nB. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\n1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of (b)(4) and (b)(4), to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using (b)(4) and (b)(4) to wipe devices which had already been cleaned on the “(b)(4)”.\n2. The “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of (b)(4) and (b)(4) stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with (b)(4) during manufacturing) or documented justification for why validation of such devices was not necessary.\nC. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “(b)(4)”. For example:\n1. Your “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “(b)(4)” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, the number of (b)(4) tested per lot for cytotoxicity and endotoxin was (b)(4) and (b)(4), respectively and the number of (b)(4) units tested for cytotoxicity, endotoxin, and particulate was (b)(4), and (b)(4), respectively. An AQL of (b)(4) for a sample size of (b)(4) and (b)(4) units per lot would have required testing on (b)(4) samples per lot for each test.\n2. Your “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, cytotoxicity testing was only conducted on (b)(4) out of (b)(4) per lot and endotoxicity and particulate testing was conducted on (b)(4) per lot. An AQL of (b)(4) would have required a sufficient number of samples to be able to test a minimum of (b)(4) samples each for endotoxins, cytotoxicity, and particulates for a lot size between (b)(4) and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the OQ for the “(b)(4)”, you plan to update the (b)(4) cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process (b)(4); removal of any adhesives; load configurations; comingling; multiple (b)(4); and (b)(4). However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process (b)(4) instead of actual products during OQ.\nWith regards to PQ for the “(b)(4)”, you dispute that (b)(4) purity of the rinse tank was not conducted at nominal; however, the (b)(4) and (b)(4) cycle was not done under normal operating conditions. You plan to update the (b)(4) cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product (b)(4). However, there was no corrective action identified to run system (b)(4) purity under normal operating conditions (≤ (b)(4) microsiemens\u002Fcm) and define the optimal degassing time.\nWith regards to the PFMEA for the “(b)(4)”, you intend to review and update the existing PFMEA as needed; contact (b)(4) of the (b)(4) customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “(b)(4)”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\nWith regards to (b)(4), you plan to “amend” the (b)(4) validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\nWith regards to process validation for additional post-production cleaning processes, you state that the use of (b)(4), and (medical grade) (b)(4) to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\nWith regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “(b)(4)” and amendment of the (b)(4) validation will utilize a statistically valid sampling plan based on documented rationale.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\nSpecifically, you failed to implement your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\nA. You failed to implement section 5.2.4.2.5 which states “(b)(4).” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large (b)(4) instrument (Part # (b)(4); WO 101395) and (b)(4) instrument (Part # (b)(4); WO 99014) in the same (b)(4) load.\nB. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: (b)(4) release instrument (Part # (b)(4); WO 98145) and (b)(4) instrument (Part # (b)(4); WO 98151), which appeared be stacked in 3 layers. In addition, the “(b)(4)\" manual specifically states that “(b)(4).”\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “(b)(4)” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and (b)(4) cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “(b)(4)” that challenges comingling will address the original purpose which was to (b)(4), as noted in your (b)(4) cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). Specifically:\nA. You have not defined and documented procedures to monitor and control the following parameters for the validated (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers:\n1. Weight of the Load (b)(4): There is no procedure to ensure that the load (b)(4) weight is below (b)(4) pounds, which was determined to be the limit during validation.\n2. Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks: There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of (b)(4)℉, which was determined to be the limit during validation.\n3. Concentration of the Cleaning Solution (i.e., Detergent): There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a (b)(4) basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\n4. Time for Degassing of Cleaning Solution (i.e., Detergent): There is no procedure to ensure that your “(b)(4)”, which operates at (b)(4)kHz, is degassed for (b)(4) to (b)(4) minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\nB. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of (b)(4)℉ to (b)(4)℉ and documentation of the temperature on the “(b)(4) Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “(b)(4)”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately (b)(4)% ((b)(4) out of (b)(4)) of the loads run on your “(b)(4)” were performed at out of specification temperatures. For example, your employees operated your (b)(4) cleaner at temperatures lower than the minimum specified limit of (b)(4)℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least (b)(4) orthopedic devices ((b)(4) implants and (b)(4) surgical instruments).\nC. You have not established a procedure for the monitoring and control of temperature and time for (b)(4). Section 6.2 of your “(b)(4)” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***(b)(4) is pre-heated***between (b)(4) and (b)(4) F for a minimum of (b)(4) prior to application.”\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “(b)(4)”; update the frequency as needed; and revise the (b)(4) cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\nWith regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is (b)(4)℉ and that the (b)(4) cleaning action only begins to deteriorate when temperatures go above certain limits (typically (b)(4)℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of (b)(4)℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below (b)(4)℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\nYou also plan to update the (b)(4) cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the (b)(4) cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the (b)(4) cleaner.\nWith regards to the inadequate monitoring and control of parameters for (b)(4), you plan to review the (b)(4) validation and establish the applicable monitoring and control and amend the (b)(4) procedure to these said controls.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\nA. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\n1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for (b)(4) blades received with metal debris, leftover burrs, and residue corresponding to (b)(4) devices (Part # (b)(4)), the corrective actions included (1) increasing clean time to (b)(4) minutes for your in-process (b)(4) cleaning machines; (2) verifying use of the custom (b)(4) fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\n2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process (b)(4) machines, may have affected other devices with similar geometries which also use the in-process (b)(4) machines to remove residue and metal shards.\n3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the (b)(4)” on at least (b)(4) devices (Part # (b)(4)) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for (b)(4) lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers ((b)(4)) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\nB. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\n1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: (b)(4)); Rejection % (Score: (b)(4)); Occurrence (Score (b)(4)); and Detectability ((b)(4)). A combined score of (b)(4) or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of (b)(4) is defined as “Almost Certain” while a score of (b)(4) is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\n2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., (b)(4) data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\n3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across (b)(4) unique part numbers.\n4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee (b)(4) categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\nWith regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples (b)(4) orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for (b)(4) associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\nWith regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score (b)(4) not lowest score (b)(4) and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\nWith regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\nA. Internal Nonconformances, found during manufacturing and inspections (excluding (b)(4) inspections – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the (b)(4) software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\nB. Internal nonconformances, only found during (b)(4) inspections conducted during manufacturing – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal (b)(4) Scrap Log” and then discards the part along with the (b)(4) report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\nSpecifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “(b)(4) Acceptance Number Sampling Plan Fifth Edition” which requires (b)(4) sampling. For example:\nA. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # (b)(4)), your personnel only used your (b)(4) to measure the critical diameter feature (b)(4) times (to include (b)(4)). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured (b)(4) times at (b)(4) since the inspection plan was specified to follow the Acceptable Quality Limit of (b)(4) (AQL (b)(4)) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of (b)(4) and (b)(4) under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in (b)(4) devices being returned and scrapped due to diameters exceeding the specified limit of (b)(4) +\u002F- (b)(4).\nB. On 5\u002F17\u002F24, our investigator observed employee (b)(4) operate the (b)(4) for machining of the metal locking date ring (Part # (b)(4)) under WO # 102106. Your operator explained that every (b)(4) piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified (b)(4) frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1). Specifically:\nA. Your procedure to define and document the schedule for the (b)(4) bowl and filter gauge pressure of the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) is inadequate. The “(b)(4)” manual requires drainage and monitoring of the (b)(4) volume on a (b)(4) basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance (b)(4) on the (b)(4) Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked (b)(4) and changed if it reaches (b)(4) PSI, there is no requirement to check the filter gauge pressure under the “(b)(4)” section of your maintenance log (or elsewhere).\nB. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your (b)(4) machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\nWe reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “(b)(4)”, you plan to review the “(b)(4)” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\nSpecifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed (b)(4) operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Phillips Precision, Inc.","phillips-precision-inc-697119-12092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024","2026-10-26T08:09:41.686932+00:00","2025-01-14","697119","Jeanne M. Phillips","2026-08-19T17:04:56.275+00:00","VIA Electronic Mail","2024-12-09",{"id":72,"raw":73,"subject":78,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":88,"closeout_date":19,"issuing_office":77,"recipient_name":19,"body_fetched_at":89,"delivery_method":90,"recipient_title":19,"reference_number":19,"action_taken_date":91,"medical_device_id":19,"response_letter_date":19},472,[74,75,76,77,78,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","Drugs","2026-08-19T14:27:25.954+00:00","Via Email","2025-11-13",{"id":93,"raw":94,"subject":99,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":83,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":23,"posted_date":106,"marcs_cms_no":107,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":108,"body_fetched_at":109,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":110,"medical_device_id":19,"response_letter_date":19},63,[95,96,97,11,98,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","2026-05-20",{"id":112,"raw":113,"subject":99,"body_html":117,"body_text":118,"firm_name":119,"letter_id":120,"created_at":121,"fei_number":19,"letter_url":122,"updated_at":123,"action_type":22,"case_status":23,"posted_date":124,"marcs_cms_no":125,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":126,"body_fetched_at":127,"delivery_method":128,"recipient_title":19,"reference_number":19,"action_taken_date":129,"medical_device_id":19,"response_letter_date":19},954,[114,115,116,11,99,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","VIA UNITED PARCEL SERVICE","2025-04-04",{"id":131,"raw":132,"subject":136,"body_html":138,"body_text":139,"firm_name":140,"letter_id":141,"created_at":142,"fei_number":19,"letter_url":143,"updated_at":144,"action_type":22,"case_status":45,"posted_date":145,"marcs_cms_no":146,"product_type":26,"closeout_date":147,"issuing_office":11,"recipient_name":148,"body_fetched_at":149,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":150,"medical_device_id":19,"response_letter_date":19},2483,[133,134,135,11,136,13,137,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":152,"raw":153,"subject":36,"body_html":157,"body_text":158,"firm_name":159,"letter_id":160,"created_at":83,"fei_number":19,"letter_url":161,"updated_at":162,"action_type":22,"case_status":23,"posted_date":163,"marcs_cms_no":164,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":165,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":166,"medical_device_id":19,"response_letter_date":19},90,[154,155,156,11,36,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-30T04:00:00Z\">04\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026\">ZOLL Medical Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ZOLL Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>269 Mill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chelmsford\u003C\u002Fspan>, \u003Cspan>ME\u003C\u002Fspan> \u003Cspan>01824\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jrennert@zoll.com\"> jrennert@zoll.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 711320\u003C\u002Fp>\u003Cp>April 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Rennert:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.&nbsp;\u003C\u002Fp>\u003Cp>For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\u003C\u002Fp>\u003Cp>For example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which requires a CAPA request per SOP-682.”\u003C\u002Fp>\u003Cp>B. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>i. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\u003C\u002Fp>\u003Cp>ii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, level \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\u003C\u002Fp>\u003Cp>iii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your firm found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports attributed to component failures and additional information on why this did not trigger a CAPA request.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\u003C\u002Fp>\u003Cp>2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\u003C\u002Fp>\u003Cp>A. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the MRI. The vent specification is for \u003Cstrong>(b)(4)\u003C\u002Fstrong> with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\u003C\u002Fp>\u003Cp>B. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when performing the MRI compatibility testing.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\u003C\u002Fp>\u003Cp>3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\u003C\u002Fp>\u003Cp>A. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\u003C\u002Fp>\u003Cp>B. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\u003C\u002Fp>\u003Cp>However, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Legacy, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a probability of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the level of risk will always be considered \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite the level of severity.\u003C\u002Fp>\u003Cp>C. You have failed to assess the risk of visible corrosion spots larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter when within the shelf life of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\u003C\u002Fp>\u003Cp>The adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the investigator during the inspection and have completed the testing and provided the testing in your response.\u003C\u002Fp>\u003Cp>Your firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents in lieu of updating the existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents. What is your rationale for risk acceptability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) determined since your risk categorization appears to be mostly \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for two out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the same hazard of algorithm analysis incorrect but the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> not \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the clinically relevant delay does not contribute to irreversible harm or death.\u003C\u002Fp>\u003Cp>4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> delivered breaths via Real BVM Help, was categorized as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier, which is defined as not directly impacting the production or quality of a device.\u003C\u002Fp>\u003Cp>B. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\u003C\u002Fp>\u003Cp>Your responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> for components used in finished devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\u003C\u002Fp>\u003Cp>Our understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.&nbsp;\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nZOLL Medical Corporation\n\n269 Mill Road\n\nChelmsford, ME 01824\n\nUnited States\n\njrennert@zoll.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711320\nApril 30, 2026\nDear Mr. Rennert:\nDuring an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.\nFor example:\nA. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\nFor example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of (b)(4), which requires a CAPA request per SOP-682.”\nB. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\ni. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\nii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of (b)(4), level (b)(4), as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\niii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\nThe responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “(b)(4)”. Your firm found that (b)(4) out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the (b)(4) reports attributed to component failures and additional information on why this did not trigger a CAPA request.\nWe cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a (b)(4) period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\n2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\nA. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately (b)(4) to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used (b)(4) away from the MRI. The vent specification is for (b)(4) with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\nB. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when performing the MRI compatibility testing.\nThe responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “(b)(4).” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\nWe cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 (b)(4) environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used (b)(4) away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\n3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential (b)(4) and (b)(4) when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\nA. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with (b)(4) employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\nB. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\nHowever, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of (b)(4) for Legacy, (b)(4) for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of (b)(4) and a probability of (b)(4), the level of risk will always be considered (b)(4) despite the level of severity.\nC. You have failed to assess the risk of visible corrosion spots larger than (b)(4) in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as (b)(4) diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than (b)(4) diameter when within the shelf life of (b)(4). Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\nThe adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share (b)(4) with the investigator during the inspection and have completed the testing and provided the testing in your response.\nYour firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new (b)(4) documents in lieu of updating the existing (b)(4) documents. What is your rationale for risk acceptability ((b)(4)) determined since your risk categorization appears to be mostly (b)(4) and (b)(4) for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of (b)(4) for two out of (b)(4) with the same hazard of algorithm analysis incorrect but the (b)(4) hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of (b)(4) not (b)(4) since the clinically relevant delay does not contribute to irreversible harm or death.\n4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\nA. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level (b)(4). The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of (b)(4) delivered breaths via Real BVM Help, was categorized as Level (b)(4). Level (b)(4) suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level (b)(4) supplier, which is defined as not directly impacting the production or quality of a device.\nB. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\nYour responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level (b)(4) and Level (b)(4) for components used in finished devices.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\nThe adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\nOur understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ZOLL Medical Corporation","zoll-medical-corporation-711320-04302026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026","2026-10-26T08:10:39.74889+00:00","2026-06-16","711320","2026-08-19T04:37:12.557+00:00","2026-04-30",{"id":168,"raw":169,"subject":172,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":121,"fei_number":19,"letter_url":177,"updated_at":178,"action_type":22,"case_status":23,"posted_date":124,"marcs_cms_no":179,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":180,"body_fetched_at":181,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":182,"medical_device_id":19,"response_letter_date":19},952,[114,170,171,11,172,13,13,13],"\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025\">Noah Medical Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noah Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2075 Zanker Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Jose\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jianzhang@noahmed.com\"> jianzhang@noahmed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #702414\u003C\u002Fp>\u003Cp>April 09, 2025\u003Cbr>\u003Cbr>Dear Ms. Zhang:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\u003C\u002Fp>\u003Cp>a. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\u003C\u002Fp>\u003Cp>b. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\u003C\u002Fp>\u003Cp>a. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\u003C\u002Fp>\u003Cp>i. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\u003C\u002Fp>\u003Cp>ii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\u003C\u002Fp>\u003Cp>iii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\u003C\u002Fp>\u003Cp>b. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\u003C\u002Fp>\u003Cp>c. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\u003C\u002Fp>\u003Cp>i. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\u003C\u002Fp>\u003Cp>ii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\u003C\u002Fp>\u003Cp>Specifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately conduct design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> biopsy tools, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration of the bronchoscope instead of \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\u003C\u002Fp>\u003Cp>b. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\u003C\u002Fp>\u003Cp>i. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\u003C\u002Fp>\u003Cp>ii. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>iii. Protocol #TP-099, Revision B, relating to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations)” and Summary Report #TR-378, Revision A.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\u003C\u002Fp>\u003Cp>a. NCR 0367 (Dated 04\u002F11\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak test due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the working channels (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, your firm did not conduct investigation to identify the root cause(s) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>b. NCR 0605 (Dated 09\u002F20\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures were due to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. NCR 0071 (Dated 07\u002F27\u002F2023) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516 (part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon the “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\u003C\u002Fp>\u003Cp>Your firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nNoah Medical Corporation\n\n2075 Zanker Road\n\nSan Jose, CA 95131\n\nUnited States\n\njianzhang@noahmed.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #702414\nApril 09, 2025\n\nDear Ms. Zhang:\nDuring an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm1. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\na. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\nb. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the (b)(4) poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the (b)(4) aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a (b)(4) aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\na. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\ni. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\nii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\niii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\nb. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\nc. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\ni. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\nii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\nSpecifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.2 For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\na. Your firm failed to adequately conduct design validation for the (b)(4) biopsy tools, such as (b)(4), listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the (b)(4) and used the (b)(4) as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a (b)(4) configuration of the bronchoscope instead of (b)(4) configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\nb. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\ni. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\nii. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\niii. Protocol #TP-099, Revision B, relating to the (b)(4) aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes (b)(4) and (b)(4) configurations)” and Summary Report #TR-378, Revision A.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\na. NCR 0367 (Dated 04\u002F11\u002F2024) involves (b)(4) bronchoscopes failing leak test due to (b)(4) in the working channels (part (b)(4)). However, your firm did not conduct investigation to identify the root cause(s) of the (b)(4) nor implement a SCAR with your supplier.\nb. NCR 0605 (Dated 09\u002F20\u002F2024) involves (b)(4) bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the (b)(4), and the other (b)(4) failures were due to (b)(4). However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed (b)(4).\nc. NCR 0071 (Dated 07\u002F27\u002F2023) involves (b)(4) working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately (b)(4) NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\n5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, (b)(4)” CRB-1516 (part number (b)(4)), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism ((b)(4)) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The (b)(4) were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the (b)(4) upon the “Galaxy, Cart, (b)(4)” CRB-1516.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\nOur inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\nYour firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\n_______________________\n1 FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\n2 Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.","Noah Medical Corporation","noah-medical-corporation-702414-04092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025","2026-10-26T08:09:34.20429+00:00","702414","Jian Zhang","2026-08-19T16:52:23.305+00:00","2025-04-09",{"id":184,"raw":185,"subject":190,"body_html":191,"body_text":192,"firm_name":193,"letter_id":194,"created_at":142,"fei_number":19,"letter_url":195,"updated_at":196,"action_type":22,"case_status":23,"posted_date":197,"marcs_cms_no":198,"product_type":88,"closeout_date":19,"issuing_office":189,"recipient_name":199,"body_fetched_at":200,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":201,"medical_device_id":19,"response_letter_date":19},2257,[186,187,188,189,190,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","2023-01-11","647603","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":203,"raw":204,"subject":36,"body_html":210,"body_text":211,"firm_name":212,"letter_id":213,"created_at":42,"fei_number":19,"letter_url":214,"updated_at":215,"action_type":22,"case_status":45,"posted_date":216,"marcs_cms_no":217,"product_type":26,"closeout_date":218,"issuing_office":208,"recipient_name":219,"body_fetched_at":220,"delivery_method":221,"recipient_title":19,"reference_number":19,"action_taken_date":222,"medical_device_id":19,"response_letter_date":19},2524,[205,206,207,208,36,13,209,13],"\u003Ctime datetime=\"2022-08-09T13:20:00Z\">08\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-12T04:00:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022\">Zyno Medical LLC\u003C\u002Fa>","Office of Medical Devices and Radiological Health Operations Div. 1 East","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintuvie-holdings-llc-629844-07162026\">\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chaoyoung Lee, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zyno Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>177 Pine Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Natick\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01760\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health Operations Div. 1 East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 629844\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 12, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported \u003Cstrong>(b)(4)\u003C\u002Fstrong> over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Approximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures &amp; forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\u003C\u002Fp>\n\n\u003Cp>Your firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>: change in sterilization method&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm waived verification testing for these design changes to the administration sets tubing stating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets were identical to a previous series (B2) of administration sets which had proven durable (\u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\u003C\u002Fli>\n\t\u003Cli>Your firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\u003C\u002Fli>\n\t\u003Cli>Your firm did not perform adequate validation of user needs for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F9\u002F19) and Usability Assessment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Three (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Complaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\u003C\u002Fp>\n\n\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\u003C\u002Fp>\n\n\u003Cp>Additionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>For example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Change in sterilization method from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\u003C\u002Fli>\n\t\u003Cli>Replacement of the spike with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drip chamber. According to your records, these changes were implemented to address new market needs.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph. D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 - East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nChaoyoung Lee, PhD\n\nRecipient Title\n\nCEO & Founder\n\nZyno Medical LLC\n\n177 Pine Street\n\nNatick, MA 01760\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health Operations Div. 1 East\n\nUnited States\n\nWARNING LETTER\n\nCMS# 629844\n\nJuly 12, 2022\n\nDear Dr. Lee:\n\nDuring an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and (b)(4) Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported (b)(4) over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\n\nApproximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\n\nApproximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\n\nApproximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures & forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\n\nYour firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets (b)(4): change in sterilization method (b)(4). For example:\n\nYour firm waived verification testing for these design changes to the administration sets tubing stating that the (b)(4) Administration sets were identical to a previous series (B2) of administration sets which had proven durable ((b)(4); dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\n\nYour firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\n\nYour firm did not perform adequate validation of user needs for (b)(4) administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F9\u002F19) and Usability Assessment for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\n\nSpecifically,\n\nThree (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\n\nFor example:\n\nComplaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nIn each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\nOur inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\n\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\n\nThe adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\n\nYour firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\n\nAdditionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFor example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\n\nChange in sterilization method from (b)(4). While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\n\nReplacement of the spike with (b)(4) and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the (b)(4) and drip chamber. According to your records, these changes were implemented to address new market needs.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThis letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph. D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 - East","Zyno Medical LLC","zyno-medical-llc-629844-07122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022","2026-10-26T08:10:40.242986+00:00","2022-08-09","629844","2026-07-21","Chaoyoung Lee, PhD","2026-08-20T01:41:20.299+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-07-12",{"id":224,"raw":225,"subject":230,"body_html":231,"body_text":232,"firm_name":233,"letter_id":234,"created_at":235,"fei_number":19,"letter_url":236,"updated_at":237,"action_type":22,"case_status":23,"posted_date":238,"marcs_cms_no":239,"product_type":240,"closeout_date":19,"issuing_office":229,"recipient_name":241,"body_fetched_at":242,"delivery_method":243,"recipient_title":19,"reference_number":244,"action_taken_date":245,"medical_device_id":19,"response_letter_date":19},21927,[226,227,228,229,230,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Biologics","Joe Spell","2026-10-27T01:19:42.766+00:00","VIA UPS and Electronic Mail","CBER 26-727246","2026-10-06",{"id":247,"raw":248,"subject":36,"body_html":252,"body_text":253,"firm_name":254,"letter_id":255,"created_at":256,"fei_number":19,"letter_url":257,"updated_at":237,"action_type":22,"case_status":23,"posted_date":258,"marcs_cms_no":259,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":260,"body_fetched_at":261,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":262,"medical_device_id":19,"response_letter_date":19},22101,[249,250,251,11,36,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-19T04:00:00Z\">08\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026\">Next Medical Products Company, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Julia M. Jacobson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Next Medical Products Company, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>45 Columbia Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Branchburg\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08876\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727918\u003C\u002Fp>\u003Cp>August 19, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Jacobson:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\u003C\u002Fp>\u003Cp>A. Section 2.0 of this procedure, which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> on each packaging line. \u003Cstrong>(b)(4)\u003C\u002Fstrong>…” is not adequate. You have not demonstrated or justified why \u003Cstrong>(b)(4)\u003C\u002Fstrong> test result can be negated simply by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations for Lots of Clear Image Ultrasound Gel that were packed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Environmental sampling was performed by your firm on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.&nbsp;\u003C\u002Fp>\u003Cp>B. Your firm’s established worst case locations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden\u003Cstrong>(b)(4)\u003C\u002Fstrong> study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\u003C\u002Fp>\u003Cp>C. Section 2.0 of this procedure, which states “The specified test regimen will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed testing with a result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates testing after the final microbial testing fails is not adequate.\u003C\u002Fp>\u003Cp>Environmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had a failing result of &gt;25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\u003C\u002Fp>\u003Cp>2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\u003C\u002Fp>\u003Cp>A. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> location taken from the dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for packaging of nonsterile Clear Image Ultrasound Gel in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of Clear Image Ultrasonic gel were packaged in \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, totaling \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases. Corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>B. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for analysis” of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were not sent to the lab until \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were tested on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>Your firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\u003C\u002Fp>\u003Cp>A. Your firm introduced a new label insert (artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rev A) between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\u003C\u002Fp>\u003Cp>B. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Specifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>The change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which contains \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), represents a change in the chemical profile compared to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Julia M. Jacobson\n\nRecipient Title\n\nPresident and CEO\n\nNext Medical Products Company, LLC\n\n45 Columbia Road\n\nBranchburg, NJ 08876\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727918\nAugust 19, 2026\nDear Ms. Jacobson:\nDuring an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\nA. Section 2.0 of this procedure, which states “(b)(4) will be conducted (b)(4) on each packaging line. (b)(4)…” is not adequate. You have not demonstrated or justified why (b)(4) test result can be negated simply by (b)(4). Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental (b)(4) locations for Lots of Clear Image Ultrasound Gel that were packed in (b)(4). Environmental sampling was performed by your firm on (b)(4) for (b)(4) for bottler dispense nozzle (b)(4) and (b)(4) dispensing nozzle (b)(4) and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on (b)(4) that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.\nB. Your firm’s established worst case locations for the (b)(4) locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden(b)(4) study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\nC. Section 2.0 of this procedure, which states “The specified test regimen will be conducted (b)(4) unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the (b)(4) failed testing with a result of ≥25,000 CFUs.\nYour firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental (b)(4) and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental (b)(4) and air plates testing after the final microbial testing fails is not adequate.\nEnvironmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\nYour firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\nYour firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The (b)(4) monitoring results for the (b)(4) had a failing result of >25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): (b)(4). Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\n2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\nA. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental (b)(4) location taken from the dispense nozzle (b)(4) used for packaging of nonsterile Clear Image Ultrasound Gel in (b)(4). The aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on (b)(4) that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots ((b)(4)) of Clear Image Ultrasonic gel were packaged in (b)(4) with (b)(4), totaling (b)(4) cases. Corrective and preventive actions were not initiated.\nB. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to (b)(4) for analysis” of the (b)(4). (b)(4) samples were collected on (b)(4) and were not sent to the lab until (b)(4). These (b)(4) samples were tested on (b)(4) and (b)(4) and the bottler dispense nozzle (b)(4), and the (b)(4) dispensing nozzle (b)(4) samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated (b)(4), corrective and preventive actions were not initiated.\nYour firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs.\nThe adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated (b)(4).\n3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\nA. Your firm introduced a new label insert (artwork (b)(4), rev A) between (b)(4) and (b)(4) for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; (b)(4) batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\nB. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from (b)(4) to (b)(4) (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\nYour firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork (b)(4), Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\nYour firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from (b)(4) to (b)(4) which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\nUnapproved Device Violation\nOur inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSpecifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from (b)(4) to (b)(4) in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\nThe change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, (b)(4) (which contains (b)(4) and (b)(4)), represents a change in the chemical profile compared to (b)(4), and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Next Medical Products Company, LLC","next-medical-products-company-llc-727918-08192026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026","2026-11-03","727918","Ms. Julia M. Jacobson","2026-11-10T01:03:13.668+00:00","2026-08-19",{"id":264,"raw":265,"subject":36,"body_html":269,"body_text":270,"firm_name":271,"letter_id":272,"created_at":83,"fei_number":19,"letter_url":273,"updated_at":274,"action_type":22,"case_status":23,"posted_date":275,"marcs_cms_no":276,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":277,"body_fetched_at":278,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":279,"medical_device_id":19,"response_letter_date":19},434,[266,267,268,11,36,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025\">Envoy Medical Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brent T. Lucas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Envoy Medical Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4875 White Bear Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55110-3325\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:blucas@envoymedical.com\"> blucas@envoymedical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 718762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Lucas:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\u003C\u002Fp>\u003Cp>a) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\u003C\u002Fp>\u003Cp>b) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\u003C\u002Fp>\u003Cp>c) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment &amp; CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\u003C\u002Fp>\u003Cp>a) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\u003C\u002Fp>\u003Cp>b) Your firm opened CAPA-00708 on July 10, 2024, for high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts discovered during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\u003C\u002Fp>\u003Cp>a) CAPA CA-00701 identified that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in assembly processes may have incomplete \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\u003C\u002Fp>\u003Cp>b) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>, while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to your firm’s Risk Management Process procedure, severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates temporary health problems requiring routine medical care, while severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\u003C\u002Fp>\u003Cp>c) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your \u003Cstrong>(b)(4) \u003C\u002Fstrong>water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> effects on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for nearly a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add \u003Cstrong>(b)(4)\u003C\u002Fstrong> risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrent T. Lucas\n\nRecipient Title\n\nCEO & Director\n\nEnvoy Medical Inc.\n\n4875 White Bear Parkway\n\nSaint Paul, MN 55110-3325\n\nUnited States\n\nblucas@envoymedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 718762\nNovember 11, 2025\nDear Mr. Lucas:\nDuring an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\na) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\nb) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\nc) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\nThe response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\n2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment & CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\na) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high (b)(4) particulate counts during (b)(4) cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of (b)(4) at location (b)(4) in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\nb) Your firm opened CAPA-00708 on July 10, 2024, for high (b)(4) particulate counts discovered during (b)(4) cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of (b)(4) at location (b)(4) and (b)(4) at location (b)(4) in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\n3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\nSpecifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\na) CAPA CA-00701 identified that (b)(4) of (b)(4) used in assembly processes may have incomplete (b)(4) due to (b)(4) excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\nb) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated (b)(4) water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity (b)(4), while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity (b)(4). According to your firm’s Risk Management Process procedure, severity (b)(4) indicates temporary health problems requiring routine medical care, while severity (b)(4) indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\nc) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your (b)(4) water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the (b)(4) water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as (b)(4) effects on (b)(4) for nearly a (b)(4), or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add (b)(4) risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Envoy Medical Inc.","envoy-medical-inc-718762-11112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025","2026-10-26T08:08:35.801946+00:00","2025-12-09","718762","Brent T. Lucas","2026-08-19T11:14:00.787+00:00","2025-11-11",{"id":281,"raw":282,"subject":286,"body_html":287,"body_text":288,"firm_name":289,"letter_id":290,"created_at":121,"fei_number":19,"letter_url":291,"updated_at":292,"action_type":22,"case_status":23,"posted_date":293,"marcs_cms_no":294,"product_type":88,"closeout_date":19,"issuing_office":77,"recipient_name":295,"body_fetched_at":296,"delivery_method":90,"recipient_title":19,"reference_number":297,"action_taken_date":298,"medical_device_id":19,"response_letter_date":19},735,[283,284,285,77,286,13,13,13],"\u003Ctime datetime=\"2025-08-05T04:00:00Z\">08\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foasis-medical-inc-707198-07152025\">Oasis Medical, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-93\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norman Craig Delgado\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Oasis Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>514 S. Vermont Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Glendora\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91741\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-93\u003C\u002Fp>\u003Cp>July 15, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Delgado:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facilities, Oasis Medical, Inc., FEI 2083373, at 514 S. Vermont Avenue, Glendora, from January 15 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 17, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure the use of reproducible manufacturing processes for the production of sterile ophthalmic drug products. You also lacked an ongoing program to establish stable manufacturing operations, monitor ongoing process control, and provide for consistent drug quality. For example,\u003C\u002Fp>\u003Cul>\u003Cli>Your process lacked adequate control and is prone to producing an excessive number of defective units. A substantial portion of batches have been rejected, including total reject levels \u003Cstrong>(b)(4)\u003C\u002Fstrong> in a number of cases. Of special concern are the excessive number of defective products due to visible particulate contamination (e.g., recurring instances of levels greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Batches with very high defect levels were nonetheless distributed.\u003C\u002Fli>\u003Cli>You failed to establish and follow an adequate visual inspection program for the ophthalmic drugs manufactured by your firm.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>There was no classification as to the severity of the defects (i.e., critical, major, minor) or limit for the number of defects allowed, if any.\u003C\u002Fp>\u003Cul>\u003Cli>The most recently completed requalification study for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle was conducted in 2023 and inadequately considered potential changes from previous qualifications and the original validation. The 2023 requalification did not include an assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance or changes to the drug product components.\u003C\u002Fli>\u003Cli>The maximum duration of the hold steps in your manufacturing process (e.g., extensive hold times prior to \u003Cstrong>(b)(4)\u003C\u002Fstrong>) has not been validated.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response fails to address your lack of process capability, and the overreliance on visual inspection in an attempt to remove excessive defective units from batches.\u003C\u002Fp>\u003Cp>You do not commit to thoroughly investigate the root causes of the visible particulates and excessive occurrence of these critical defects. You also lack appropriate interim steps to prevent production of further batches from a low capability process while you make efforts to remediate it. In addition, the response lacks a commitment to address potentially contaminated products in distribution.\u003C\u002Fp>\u003Cp>Regarding the visual inspection program, your response lacks a commitment to perform a comprehensive reassessment of this program.\u003C\u002Fp>\u003Cp>Regarding production hold times, your response acknowledges that you have not performed validation of your hold steps. But you do not commit to validating all in-process hold times and include a date by which these studies will be completed.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process through its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed retrospective review and assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> program. The retrospective review and assessment should include all changes to the drug product, container closure system, and packaging (e.g., canula sheath); and an evaluation of changes to, and maintenance of, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment. If changes are identified, provide your plan to evaluate the safety and quality of distributed finished products that remain within expiry and a plan to ensure the safety and quality of your drug products until the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process is successfully validated.\u003C\u002Fli>\u003Cli>Thorough investigation(s), including corrective actions and preventive actions (CAPA), regarding finished product batches manufactured and released for distribution despite high numbers of rejected units.\u003C\u002Fli>\u003Cli>Complete results of your examination of retains\u002Freserve samples for all batches from January 2023 to present for defects, and any related investigation(s) and corrective actions.\u003C\u002Fli>\u003Cli>A list of all batches since January 1, 2023, to present, with the following information:\u003Cbr>o Product name\u003Cbr>o Batch number\u003Cbr>o Date of manufacture\u003Cbr>o Date of expiration\u003Cbr>o Batch size (original quantity of theoretical syringes)\u003Cbr>o Actual batch yield (number of pouched syringe units)\u003Cbr>o Number of rejects due to particulates\u003Cbr>o Number of rejects due to other defects (include the top 3 other defect types for each batch, beyond particulate defects)\u003Cbr>o Percent yield\u003C\u002Fli>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for systems used in the visual inspection of sterile drugs for defects (including but not limited to particulate matter). The assessment should include adequacy of inspection methods, acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed, and provisions for periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, summarize the program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Timelines for completing further PPQ studies on remediated processes for marketed drug products for which a state of control has not been adequately established.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacked meaningful investigations of failed sterility and bioburden test results. For example:\u003C\u002Fp>\u003Cp>\u003Cem>Sterility Failure\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately investigate a failed sterility test result for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, VISCO SHIELD Topical Drops, lot V0724N. Your external testing laboratory performs two sterility tests: one for the contents within the syringe and the other for the sterility of the syringe and cap primary packaging components. Your external testing laboratory reported a sterility failure for the syringe and cap portion of the testing. You concluded in NCR 24014 that, because the contaminant was found only on the syringe and cap and not the contents of the syringe, the likely root cause of the sterility failure was laboratory contamination due to excessive handling during the test. However, your contract testing laboratory’s investigation concluded that there was no laboratory error. You failed to resolve the conflicting root cause conclusions and did not extend your investigation to other potential sources of contamination or ensure it was of appropriate scope. Although the batch remained under your control, your QU had dispositioned this batch “USE AS IS” on September 30, 2024, to be distributed to the U.S. market.\u003C\u002Fp>\u003Cp>In your response to the sterility failure, we acknowledge your intention to create a specific procedure to address external laboratory out-of-specification (OOS) investigations. However, your investigation failed to consider conditions that led to the sterility failure or determine potential root causes to ensure effective CAPAs were promptly initiated. Additionally, you do not adequately address the potential non-integrity failure mode of the packaged finished drug product (e.g., breach in packaging integrity following \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>\u003Cem>Bioburden OOS\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not adequately investigate your firm’s pre-sterilization bioburden results that exceeded their specifications (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for VISCO SHIELD Topical Drops, lot V0724G. One sample exceeded the specification for the aerobic plate count test with a result of 570 CFU\u002Fsample and another sample exceeded the specification for the yeast and mold count test with a result of 334 CFU\u002Fsample.\u003C\u002Fp>\u003Cp>In your response to the bioburden OOS, your investigation fails to consider the conditions that led to the OOS. You do not identify the microbes recovered or determine resistance of any spore-forming microbes that may have been present. You also do not address potential root causes during the production process that could contribute to excess bioburden. Assessment of the number of types of microbes in pre-sterilization bioburden helps to determine whether the validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> process continues to be capable of rendering the finished product sterile.\u003C\u002Fp>\u003Cp>Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\u003C\u002Fp>\u003Cp>For more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance generally applies to chemistry-based laboratory testing, many of the principles are relevant to microbiological testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The disposition status of the referenced batch, VISCO SHIELD Topical Drops, lot V0724N. If the lot was released for distribution, provide the dates of release and distribution.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>o QU oversight of laboratory investigations.\u003Cbr>o Identification of adverse laboratory control trends.\u003Cbr>o Resolution of causes of laboratory variation.\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\u003Cbr>o Adequately scoping of each investigation and its CAPA.\u003Cbr>o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fli>\u003Cli>A detailed retrospective review and assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> program. The retrospective review and assessment should include:\u003Cbr>o All changes to the drug product, container closure system, and packaging (e.g., canula sheath).\u003Cbr>o An evaluation of changes to, and maintenance of, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment.\u003Cbr>o A plan to evaluate the safety and quality of distributed finished products that remain within expiry if significant changes occurred that may pose a risk to quality or safety.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. You also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.160(b)) and (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Finished Product Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your finished product testing for release of ophthalmic drug product batches did not include adequate analytical testing to determine the identification or assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose).\u003C\u002Fp>\u003Cp>Your response and subsequent updates are inadequate. You commit to updating your finished product specifications. However, you reference an internally-developed, non-specific method for assay (strength) without providing adequate documentation and scientific justification to support its use. In contrast, a method is available in the USP that employs a reference standard and spectrophotometric measurements to determine Hypromellose assay.\u003C\u002Fp>\u003Cp>\u003Cem>Stability Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacked an adequate stability program to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm did not establish appropriate tests and specifications for your ophthalmic drug products to monitor the active ingredient identity or assay at release and throughout expiry. Your stability program did not include an adequate test for assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose). In place of the USP assay, your firm used an in-house method based on loss-on-drying without scientific justification.\u003C\u002Fli>\u003Cli>Your firm did not follow your Operational Procedure,\u003Cem> Control, Testing, and Release of Drug Products\u003C\u002Fem>, which requires placement of samples from one commercial batch of each product on the stability program each year, and testing at \u003Cstrong>(b)(4)\u003C\u002Fstrong> intervals. Your 2023 batch was delayed in its entry to your stability program and your 2024 testing was not initiated. A similar pattern of non-compliance was noted during your 2018 inspection.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response is inadequate. You reference stability studies from batches made in 2013 and 2016 to justify reduced stability testing intervals. You fail to provide a root cause or an adequate CAPA to address the failure to follow your own stability procedure.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Without sufficient release and ongoing stability testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The method validation protocol, report, and supporting data for your current Hypromellose assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s QU failed to adequately execute its responsibilities.\u003C\u002Fp>\u003Cp>This includes oversight of both internal and external manufacturing activities, including laboratory services.\u003C\u002Fp>\u003Cp>Regarding functions that occurred at your facility, the records and information you provided demonstrate that your QU did not effectively exercise its responsibilities to oversee the quality of your ophthalmic drug manufacturing operations. Your firm failed to follow established procedures. For example, you had not conducted annual product reviews since 2018, which was cited as an observation in a previous inspection. In addition, your firm did not conduct annual examinations of reserve samples for the past 2 years.\u003C\u002Fp>\u003Cp>Regarding external functions performed on your behalf, your ongoing oversight of critical contract services was insufficient.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. Our inspectional findings indicate that your QU is not conducting appropriate oversight of drug CGMP operations.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to addressing the observations we identified, your response lacks detail on systemic remediations needed for your QU and your quality system.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2083373 and ATTN: Carrie A. Hughes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-93\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norman Craig Delgado\n\nRecipient Title\n\nPresident and CEO\n\nOasis Medical, Inc.\n\n514 S. Vermont Avenue\n\nGlendora, CA 91741\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-93\nJuly 15, 2025\nDear Mr. Delgado:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facilities, Oasis Medical, Inc., FEI 2083373, at 514 S. Vermont Avenue, Glendora, from January 15 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 17, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to ensure the use of reproducible manufacturing processes for the production of sterile ophthalmic drug products. You also lacked an ongoing program to establish stable manufacturing operations, monitor ongoing process control, and provide for consistent drug quality. For example,\nYour process lacked adequate control and is prone to producing an excessive number of defective units. A substantial portion of batches have been rejected, including total reject levels (b)(4) in a number of cases. Of special concern are the excessive number of defective products due to visible particulate contamination (e.g., recurring instances of levels greater than (b)(4)). Batches with very high defect levels were nonetheless distributed.\nYou failed to establish and follow an adequate visual inspection program for the ophthalmic drugs manufactured by your firm.\nThere was no classification as to the severity of the defects (i.e., critical, major, minor) or limit for the number of defects allowed, if any.\nThe most recently completed requalification study for your (b)(4) cycle was conducted in 2023 and inadequately considered potential changes from previous qualifications and the original validation. The 2023 requalification did not include an assessment of (b)(4) maintenance or changes to the drug product components.\nThe maximum duration of the hold steps in your manufacturing process (e.g., extensive hold times prior to (b)(4)) has not been validated.\nYour response fails to address your lack of process capability, and the overreliance on visual inspection in an attempt to remove excessive defective units from batches.\nYou do not commit to thoroughly investigate the root causes of the visible particulates and excessive occurrence of these critical defects. You also lack appropriate interim steps to prevent production of further batches from a low capability process while you make efforts to remediate it. In addition, the response lacks a commitment to address potentially contaminated products in distribution.\nRegarding the visual inspection program, your response lacks a commitment to perform a comprehensive reassessment of this program.\nRegarding production hold times, your response acknowledges that you have not performed validation of your hold steps. But you do not commit to validating all in-process hold times and include a date by which these studies will be completed.\nProcess validation evaluates the soundness of design and state of control of a process through its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed retrospective review and assessment of your (b)(4) program. The retrospective review and assessment should include all changes to the drug product, container closure system, and packaging (e.g., canula sheath); and an evaluation of changes to, and maintenance of, the (b)(4) equipment. If changes are identified, provide your plan to evaluate the safety and quality of distributed finished products that remain within expiry and a plan to ensure the safety and quality of your drug products until the (b)(4) process is successfully validated.\nThorough investigation(s), including corrective actions and preventive actions (CAPA), regarding finished product batches manufactured and released for distribution despite high numbers of rejected units.\nComplete results of your examination of retains\u002Freserve samples for all batches from January 2023 to present for defects, and any related investigation(s) and corrective actions.\nA list of all batches since January 1, 2023, to present, with the following information:\no Product name\no Batch number\no Date of manufacture\no Date of expiration\no Batch size (original quantity of theoretical syringes)\no Actual batch yield (number of pouched syringe units)\no Number of rejects due to particulates\no Number of rejects due to other defects (include the top 3 other defect types for each batch, beyond particulate defects)\no Percent yield\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive, independent assessment and remediation plan for systems used in the visual inspection of sterile drugs for defects (including but not limited to particulate matter). The assessment should include adequacy of inspection methods, acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed, and provisions for periodic independent reassessment of the plan’s effectiveness.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, summarize the program for qualification of your equipment and facility.\nTimelines for completing further PPQ studies on remediated processes for marketed drug products for which a state of control has not been adequately established.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm lacked meaningful investigations of failed sterility and bioburden test results. For example:\nSterility Failure\nYour quality unit (QU) did not adequately investigate a failed sterility test result for your (b)(4) drug product, VISCO SHIELD Topical Drops, lot V0724N. Your external testing laboratory performs two sterility tests: one for the contents within the syringe and the other for the sterility of the syringe and cap primary packaging components. Your external testing laboratory reported a sterility failure for the syringe and cap portion of the testing. You concluded in NCR 24014 that, because the contaminant was found only on the syringe and cap and not the contents of the syringe, the likely root cause of the sterility failure was laboratory contamination due to excessive handling during the test. However, your contract testing laboratory’s investigation concluded that there was no laboratory error. You failed to resolve the conflicting root cause conclusions and did not extend your investigation to other potential sources of contamination or ensure it was of appropriate scope. Although the batch remained under your control, your QU had dispositioned this batch “USE AS IS” on September 30, 2024, to be distributed to the U.S. market.\nIn your response to the sterility failure, we acknowledge your intention to create a specific procedure to address external laboratory out-of-specification (OOS) investigations. However, your investigation failed to consider conditions that led to the sterility failure or determine potential root causes to ensure effective CAPAs were promptly initiated. Additionally, you do not adequately address the potential non-integrity failure mode of the packaged finished drug product (e.g., breach in packaging integrity following (b)(4)).\nBioburden OOS\nYour firm did not adequately investigate your firm’s pre-sterilization bioburden results that exceeded their specifications ((b)(4)) for VISCO SHIELD Topical Drops, lot V0724G. One sample exceeded the specification for the aerobic plate count test with a result of 570 CFU\u002Fsample and another sample exceeded the specification for the yeast and mold count test with a result of 334 CFU\u002Fsample.\nIn your response to the bioburden OOS, your investigation fails to consider the conditions that led to the OOS. You do not identify the microbes recovered or determine resistance of any spore-forming microbes that may have been present. You also do not address potential root causes during the production process that could contribute to excess bioburden. Assessment of the number of types of microbes in pre-sterilization bioburden helps to determine whether the validated (b)(4) process continues to be capable of rendering the finished product sterile.\nWhenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\nFor more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance generally applies to chemistry-based laboratory testing, many of the principles are relevant to microbiological testing.\nIn response to this letter, provide:\nThe disposition status of the referenced batch, VISCO SHIELD Topical Drops, lot V0724N. If the lot was released for distribution, provide the dates of release and distribution.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no QU oversight of laboratory investigations.\no Identification of adverse laboratory control trends.\no Resolution of causes of laboratory variation.\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\no Adequately scoping of each investigation and its CAPA.\no Revised OOS investigation procedures with these and other remediations.\nA detailed retrospective review and assessment of your (b)(4) program. The retrospective review and assessment should include:\no All changes to the drug product, container closure system, and packaging (e.g., canula sheath).\no An evaluation of changes to, and maintenance of, the (b)(4) equipment.\no A plan to evaluate the safety and quality of distributed finished products that remain within expiry if significant changes occurred that may pose a risk to quality or safety.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. You also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.160(b)) and (21 CFR 211.166(a)).\nFinished Product Testing\nYour finished product testing for release of ophthalmic drug product batches did not include adequate analytical testing to determine the identification or assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose).\nYour response and subsequent updates are inadequate. You commit to updating your finished product specifications. However, you reference an internally-developed, non-specific method for assay (strength) without providing adequate documentation and scientific justification to support its use. In contrast, a method is available in the USP that employs a reference standard and spectrophotometric measurements to determine Hypromellose assay.\nStability Program\nYour firm lacked an adequate stability program to support the (b)(4) expiration date. For example:\nYour firm did not establish appropriate tests and specifications for your ophthalmic drug products to monitor the active ingredient identity or assay at release and throughout expiry. Your stability program did not include an adequate test for assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose). In place of the USP assay, your firm used an in-house method based on loss-on-drying without scientific justification.\nYour firm did not follow your Operational Procedure, Control, Testing, and Release of Drug Products, which requires placement of samples from one commercial batch of each product on the stability program each year, and testing at (b)(4) intervals. Your 2023 batch was delayed in its entry to your stability program and your 2024 testing was not initiated. A similar pattern of non-compliance was noted during your 2018 inspection.\nYour response is inadequate. You reference stability studies from batches made in 2013 and 2016 to justify reduced stability testing intervals. You fail to provide a root cause or an adequate CAPA to address the failure to follow your own stability procedure.\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Without sufficient release and ongoing stability testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\nIn response to this letter, provide:\nThe method validation protocol, report, and supporting data for your current Hypromellose assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\nYour firm’s QU failed to adequately execute its responsibilities.\nThis includes oversight of both internal and external manufacturing activities, including laboratory services.\nRegarding functions that occurred at your facility, the records and information you provided demonstrate that your QU did not effectively exercise its responsibilities to oversee the quality of your ophthalmic drug manufacturing operations. Your firm failed to follow established procedures. For example, you had not conducted annual product reviews since 2018, which was cited as an observation in a previous inspection. In addition, your firm did not conduct annual examinations of reserve samples for the past 2 years.\nRegarding external functions performed on your behalf, your ongoing oversight of critical contract services was insufficient.\nYour QU is responsible for fully exercising its authority and responsibilities. Our inspectional findings indicate that your QU is not conducting appropriate oversight of drug CGMP operations.\nYour response is inadequate. Although you commit to addressing the observations we identified, your response lacks detail on systemic remediations needed for your QU and your quality system.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2083373 and ATTN: Carrie A. Hughes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Oasis Medical, Inc.","oasis-medical-inc-707198-07152025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foasis-medical-inc-707198-07152025","2026-10-26T08:09:36.575698+00:00","2025-08-05","707198","Mr. Norman Craig Delgado","2026-08-19T16:31:41.001+00:00","320-25-93","2025-07-15",{"id":300,"raw":301,"subject":78,"body_html":305,"body_text":306,"firm_name":307,"letter_id":308,"created_at":121,"fei_number":19,"letter_url":309,"updated_at":310,"action_type":22,"case_status":23,"posted_date":311,"marcs_cms_no":312,"product_type":313,"closeout_date":19,"issuing_office":77,"recipient_name":314,"body_fetched_at":315,"delivery_method":316,"recipient_title":19,"reference_number":317,"action_taken_date":318,"medical_device_id":19,"response_letter_date":19},762,[302,303,304,77,78,13,13,13],"\u003Ctime datetime=\"2025-07-22T04:00:00Z\">07\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-09T04:00:00Z\">07\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-chemical-corporation-706007-07092025\">Medical Chemical Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-91\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Emmanuel R. Didier\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medical Chemical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>19250 Van Ness Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Torrance\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90501-1102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-91\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Didier:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Chemical Corporation, FEI 2013736, at 19430 Van Ness Avenue, Torrance, from February 12 to 18, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “MED CHEM Tincture Green Soap” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>Furthermore, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that your drug products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, are not properly listed as required by section 510(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Your firm has not fulfilled its listing obligations under 510(j) of the FD&amp;C Act and 21 CFR 207, which is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your February 28, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, including hand sanitizers, Tincture Green Soap USP, and Isopropyl Alcohol 70% v\u002Fv. You failed to adequately perform identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC topical drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Products Containing Ethyl Alcohol and Isopropyl Alcohol\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming component ethyl alcohol (ethanol), used as an active pharmaceutical ingredient (API), for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>Furthermore, you failed to demonstrate that the component alcohol (“C40B \u003Cstrong>(b)(4)\u003C\u002Fstrong> PROOF SDA 40B ETHYL ALCOHOL BULK”), used to manufacture your drug product Tincture Green Soap USP, meets United States Pharmacopoeia (USP) monograph specifications. For example, we reviewed your raw material specification for your component alcohol and note that the specifications failed to demonstrate performance of the USP monograph identification parts A, B, and C.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you perform identity testing, use raw materials certified by trusted suppliers, and have added or will add certain assays to your specifications. Your response is inadequate because you do not provide adequate details to demonstrate identity testing meets all compendial requirements. Furthermore, your response does not address testing your high-risk drug components for DEG or EG contamination, or test ethanol for the presence of methanol contamination. Also, you do not address the potential impact on drug products in the U.S. market within expiry.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol, isopropyl alcohol, glycerin, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You used “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” as a component to manufacture your OTC topical drug products. However, you have not established that the water system is adequately designed, maintained, and monitored to ensure that it consistently produces water suitable for its intended use. You lacked water system validation and failed to conduct total organic carbon (TOC) testing to ensure that your component water met \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water United States Pharmacopeia (USP) monograph specifications.\u003C\u002Fp>\u003Cp>Additionally, you obtained excessive microbial growth from the point of use, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> (No hose)” location, following \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system maintenance sanitization cycles. The inadequate control of your water system poses a potential risk for objectionable microbiological contamination into your drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you will “revalidate” your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system and include TOC testing in your water specification. Your response is inadequate because you do not provide your initial water system validation, nor do you provide adequate details regarding your plan for performing water system validation, maintenance, and testing of the water system. Furthermore, you do not provide a timeline for the validation of your methods, nor do you consider retrospective testing of retained finished drug products that used water.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\u003C\u002Fp>\u003Cp>Furthermore, test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> water systems are generally tighter than your proposed action limits for the topical liquid dosage forms produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>Validation of your microbiological test methods, including growth promotion testing, demonstrating they are equivalent to, or better than USP compendial methods, and suitable for their intended use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform adequate oversight for the manufacture and testing of your OTC topical drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment and review of adequate batch production and control records for each batch of drug product which include complete information regarding each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fli>\u003Cli>Establishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you have added the mixing time to the batch record, and you maintain a temperature log of your incubator. Your response is inadequate because you do not provide sufficient details to demonstrate your QU will ensure the establishment and review of manufacturing records.\u003C\u002Fp>\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, complete manufacturing records are necessary to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each of your drug product before making a disposition decision, and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“MED CHEM Tincture Green Soap” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims observed on the “MED CHEM Tincture Green Soap” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>&nbsp; “Drug Facts Active Ingredients Ethyl Alcohol, 30% Purpose Antiseptic Uses Intended for . . . mild antisepsis of skin . . . Directions Mix with water. Lather and rinse” [from the product label]\u003C\u002Fp>\u003Cp>Based on the above labeling claims, “MED CHEM Tincture Green Soap” is intended for use as a topical antiseptic drug product. This topical antiseptic product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “MED CHEM Tincture Green Soap” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Over-the-Counter (OTC) topical and oral antiseptic drug products have been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use”, Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, benzethonium chloride, and chloroxylenol) were classified as Category III for use in consumer antiseptic wash products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic wash.\u003C\u002Fp>\u003Cp>Section 505G of the FD&amp;C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\u003Cp>However, “MED CHEM Tincture Green Soap” does not conform to the 1994 TFM, as further amended by the Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505. The “MED CHEM Tincture Green Soap” product labeling states that its active ingredient is “Ethyl Alcohol, 30%” and provides the following directions for use: “Mix with water. Lather and rinse.” Your “MED CHEM Tincture Green Soap” product does not conform to the 1994 TFM as further amended or any other TFM or proposed or final rule. As noted above, ethyl alcohol is not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>Accordingly, your product does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003Cbr>The introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Additionally, “MED CHEM Tincture Green Soap” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violations section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for establishment registration and listing of drug products. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, were not certified as required, thus they were inactivated by FDA in January 2024.\u003C\u002Fp>\u003Cp>Therefore, your products Tincture Green and Isopropyl Alcohol are not properly listed under section 510(j) of the FD&amp;C Act, rendering these drugs to be misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). In addition, failure to provide listing information in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing, electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>We note that several of your firm’s drug listings are inactivated\u002Funcertified. Firms must discontinue listed products when manufacturing and commercial distribution cease by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all products manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at \u003Cem>Electronic Drug Registration and Listing Instructions.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2013736 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that “tincture of green soap” was not evaluated as part of the consumer antiseptic wash rulemaking and was not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products. On June 19, 2008, FDA issued a proposed rule that would determine that there were inadequate data to establish general recognition of safety and effectiveness for tincture of green soap for use as the active ingredient in a nonantimicrobial skin wound cleanser product. “Status of Certain Additional Over-the-Counter Drug Category II Active Ingredients,” Proposed Rule, 73 FR 34895, 34901 (June 19, 2008).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-91\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Emmanuel R. Didier\n\nRecipient Title\n\nPresident and CEO\n\nMedical Chemical Corporation\n\n19250 Van Ness Avenue\n\nTorrance, CA 90501-1102\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-91\nJuly 9, 2025\nDear Mr. Didier:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Chemical Corporation, FEI 2013736, at 19430 Van Ness Avenue, Torrance, from February 12 to 18, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “MED CHEM Tincture Green Soap” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nFurthermore, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that your drug products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, are not properly listed as required by section 510(j) of the FD&C Act.\nYour firm has not fulfilled its listing obligations under 510(j) of the FD&C Act and 21 CFR 207, which is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nCGMP Violations\nWe reviewed your February 28, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures over-the-counter (OTC) topical drug products, including hand sanitizers, Tincture Green Soap USP, and Isopropyl Alcohol 70% v\u002Fv. You failed to adequately perform identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC topical drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nProducts Containing Ethyl Alcohol and Isopropyl Alcohol\nYou failed to adequately test your incoming component ethyl alcohol (ethanol), used as an active pharmaceutical ingredient (API), for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nFurthermore, you failed to demonstrate that the component alcohol (“C40B (b)(4) PROOF SDA 40B ETHYL ALCOHOL BULK”), used to manufacture your drug product Tincture Green Soap USP, meets United States Pharmacopoeia (USP) monograph specifications. For example, we reviewed your raw material specification for your component alcohol and note that the specifications failed to demonstrate performance of the USP monograph identification parts A, B, and C.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\nIdentity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that you perform identity testing, use raw materials certified by trusted suppliers, and have added or will add certain assays to your specifications. Your response is inadequate because you do not provide adequate details to demonstrate identity testing meets all compendial requirements. Furthermore, your response does not address testing your high-risk drug components for DEG or EG contamination, or test ethanol for the presence of methanol contamination. Also, you do not address the potential impact on drug products in the U.S. market within expiry.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure acceptable quality parameters are met.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol, isopropyl alcohol, glycerin, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou used “(b)(4) water” as a component to manufacture your OTC topical drug products. However, you have not established that the water system is adequately designed, maintained, and monitored to ensure that it consistently produces water suitable for its intended use. You lacked water system validation and failed to conduct total organic carbon (TOC) testing to ensure that your component water met (b)(4) Water United States Pharmacopeia (USP) monograph specifications.\nAdditionally, you obtained excessive microbial growth from the point of use, “(b)(4) (No hose)” location, following (b)(4) water system maintenance sanitization cycles. The inadequate control of your water system poses a potential risk for objectionable microbiological contamination into your drug products.\nIn your response, you state that you will “revalidate” your (b)(4) water system and include TOC testing in your water specification. Your response is inadequate because you do not provide your initial water system validation, nor do you provide adequate details regarding your plan for performing water system validation, maintenance, and testing of the water system. Furthermore, you do not provide a timeline for the validation of your methods, nor do you consider retrospective testing of retained finished drug products that used water.\n(b)(4) water for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\nFurthermore, test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established.\nIn response to this letter, provide:\nA (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for (b)(4) water systems are generally tighter than your proposed action limits for the topical liquid dosage forms produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\nValidation of your microbiological test methods, including growth promotion testing, demonstrating they are equivalent to, or better than USP compendial methods, and suitable for their intended use.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to perform adequate oversight for the manufacture and testing of your OTC topical drug products. For example, your QU failed to ensure the following:\nEstablishment and review of adequate batch production and control records for each batch of drug product which include complete information regarding each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\nEstablishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).\nIn your response, you state that you have added the mixing time to the batch record, and you maintain a temperature log of your incubator. Your response is inadequate because you do not provide sufficient details to demonstrate your QU will ensure the establishment and review of manufacturing records.\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, complete manufacturing records are necessary to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\nAn adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA list of chemical and microbial test methods and specifications used to analyze each of your drug product before making a disposition decision, and the associated written procedures.\nUnapproved New Drug and Misbranded Drug Violations\n“MED CHEM Tincture Green Soap” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of claims observed on the “MED CHEM Tincture Green Soap” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n“Drug Facts Active Ingredients Ethyl Alcohol, 30% Purpose Antiseptic Uses Intended for . . . mild antisepsis of skin . . . Directions Mix with water. Lather and rinse” [from the product label]\nBased on the above labeling claims, “MED CHEM Tincture Green Soap” is intended for use as a topical antiseptic drug product. This topical antiseptic product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “MED CHEM Tincture Green Soap” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nOver-the-Counter (OTC) topical and oral antiseptic drug products have been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use”, Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, benzethonium chloride, and chloroxylenol) were classified as Category III for use in consumer antiseptic wash products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic wash.\nSection 505G of the FD&C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\nHowever, “MED CHEM Tincture Green Soap” does not conform to the 1994 TFM, as further amended by the Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505. The “MED CHEM Tincture Green Soap” product labeling states that its active ingredient is “Ethyl Alcohol, 30%” and provides the following directions for use: “Mix with water. Lather and rinse.” Your “MED CHEM Tincture Green Soap” product does not conform to the 1994 TFM as further amended or any other TFM or proposed or final rule. As noted above, ethyl alcohol is not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products.1\nAccordingly, your product does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\nThe introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAdditionally, “MED CHEM Tincture Green Soap” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violations section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nDrug Listing Violations\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for establishment registration and listing of drug products. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.2 Your products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, were not certified as required, thus they were inactivated by FDA in January 2024.\nTherefore, your products Tincture Green and Isopropyl Alcohol are not properly listed under section 510(j) of the FD&C Act, rendering these drugs to be misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). In addition, failure to provide listing information in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing, electronic health records, insurance reimbursement, and patient education.\nWe note that several of your firm’s drug listings are inactivated\u002Funcertified. Firms must discontinue listed products when manufacturing and commercial distribution cease by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all products manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2013736 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________________\n1 We note that “tincture of green soap” was not evaluated as part of the consumer antiseptic wash rulemaking and was not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products. On June 19, 2008, FDA issued a proposed rule that would determine that there were inadequate data to establish general recognition of safety and effectiveness for tincture of green soap for use as the active ingredient in a nonantimicrobial skin wound cleanser product. “Status of Certain Additional Over-the-Counter Drug Category II Active Ingredients,” Proposed Rule, 73 FR 34895, 34901 (June 19, 2008).\n2 See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).","Medical Chemical Corporation","medical-chemical-corporation-706007-07092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-chemical-corporation-706007-07092025","2026-10-26T08:09:22.922674+00:00","2025-07-22","706007","Drugs Over-the-Counter Drugs","Mr. Emmanuel R. Didier","2026-08-19T16:34:05.655+00:00","VIA UPS","320-25-91","2025-07-09",{"id":320,"raw":321,"subject":326,"body_html":327,"body_text":328,"firm_name":329,"letter_id":330,"created_at":62,"fei_number":19,"letter_url":331,"updated_at":332,"action_type":22,"case_status":23,"posted_date":333,"marcs_cms_no":334,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":335,"body_fetched_at":336,"delivery_method":90,"recipient_title":19,"reference_number":19,"action_taken_date":337,"medical_device_id":19,"response_letter_date":19},1152,[322,323,324,11,325,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-11T04:00:00Z\">10\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024\">Adept Medical Ltd. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Murray Fenton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder, CEO and Guiding Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Medical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-6 Mc Donald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morningside\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Auckland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fenton:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\u003C\u002Fp>\n\n\u003Cp>2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Biological Indicator is an off the shelf product from supplier where \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\u003C\u002Fli>\n\t\u003Cli>The BI is packaged in a foil pouch designed to protect the product from humidity excursions.\u003C\u002Fli>\n\t\u003Cli>The potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine whether sterility was compromised.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's ultrasonic cleaning process using the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is not adequately validated according to your firm's Manufacturing Process&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\u003C\u002Fp>\n\n\u003Cp>2) During the inspection, your firm stated that it had not validated the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>process for the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm&nbsp;stated that the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp; Adept Medical also confirmed during the inspection that&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;had not validated the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and that prior to Spring 2023,&nbsp;\u003Cstrong>(b)(4) \u003C\u002Fstrong>the\u003Cstrong>&nbsp;\u003C\u002Fstrong>NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>who also did not have a&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> NeoZoline Ventilation Tube.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is an existing validated sterilization process indicating a sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Annual bioburden results of pre-cleaned devices have bioburden levels below&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU.\u003C\u002Fli>\n\t\u003Cli>Current validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm has not provided any evidence to substantiate your claims that the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>sterility assurance level or the bioburden limits below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\u003C\u002Fp>\n\n\u003Cp>1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>The FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The NC records did not adequately document the evaluation of the identified nonconformities.\u003C\u002Fli>\n\t\u003Cli>The rationale for not conducting related investigations was inadequately documented in all six NC records.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm explained that incoming NeoZoline Ventilation Tubes \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>are not inspected upon arrival.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Your firm further stated that they \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>This target achievement was cited as the reason for not taking further action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\u003C\u002Fp>\n\n\u003Cp>5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm was asked whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the NeoZoline ventilation tubes was validated&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated you have no knowledge or documentation regarding&nbsp;whether the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for the NeoZoline Ventilation Tubes had been properly&nbsp;validated.&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical learned the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;units of NeoZoline Ventilation Tubes in various types from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between June 2023 and November 2023. They released \u003Cstrong>(b)(4) \u003C\u002Fstrong>units\u003Cstrong>&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;&nbsp;\u003C\u002Fstrong>Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>indicated no adverse events.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Post market surveillance data indicated we have had no product safety or performance complaints since product launch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;the NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>did not have any documentation that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>device was validated.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Any \u003Cstrong>(b)(4)\u003C\u002Fstrong> may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that it can be properly sterilized without&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> becoming unsafe. The change in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Registrar Corp.,\u003Cbr>\n144 Research Drive,\u003Cbr>\nHampton, Virginia,\u003Cbr>\nUSA 23666\u003Cbr>\nPhone: Tel: 1-757-224-0177, Ext.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nEmail:\u003Cstrong>(b)(4)\u003C\u002Fstrong>@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Murray Fenton\n\nRecipient Title\n\nFounder, CEO and Guiding Director\n\nAdept Medical Ltd.\n\n2-6 Mc Donald Street\n\nMorningside\n\nAuckland\n\nNew Zealand\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nOctober 11, 2024\n\nDear Mr. Fenton:\n\nDuring an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\n\nFor example:\n\n1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator (b)(4) (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by (b)(4) with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or (b)(4) Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the (b)(4) Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\n\n2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. (b)(4). Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties. (b)(4)\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\n\nThe (b)(4) Biological Indicator is an off the shelf product from supplier where (b)(4) has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\n\nThe BI is packaged in a foil pouch designed to protect the product from humidity excursions.\n\nThe potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\n\nAdditionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\n\n(b)(4)\n\nBased on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. (b)(4) your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\n\nAdditionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator (b)(4) to determine whether sterility was compromised.\n\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\n\n1) Your firm's ultrasonic cleaning process using the (b)(4) Cleaner (b)(4) is not adequately validated according to your firm's Manufacturing Process (b)(4). During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\n\n2) During the inspection, your firm stated that it had not validated the (b)(4) process for the NeoZoline Ventilation Tube (b)(4). Your firm stated that the (b)(4). Adept Medical also confirmed during the inspection that (b)(4) had not validated the NeoZoline Ventilation Tube (b)(4) and that prior to Spring 2023, (b)(4) the NeoZoline Ventilation Tube (b)(4) who also did not have a (b)(4) NeoZoline Ventilation Tube.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\n\nThere is an existing validated sterilization process indicating a sterility assurance level of (b)(4)\n\nAnnual bioburden results of pre-cleaned devices have bioburden levels below (b)(4) CFU.\n\nCurrent validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm has not provided any evidence to substantiate your claims that the (b)(4) sterility assurance level or the bioburden limits below (b)(4) CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the (b)(4) Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\n\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\n\nYour firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\n\n1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\n\n2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\n\n3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure (b)(4) the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure (b)(4)\n\nYour firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\n\nThe FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\n\nThe NC records did not adequately document the evaluation of the identified nonconformities.\n\nThe rationale for not conducting related investigations was inadequately documented in all six NC records.\n\nYour firm explained that incoming NeoZoline Ventilation Tubes (b)(4) are not inspected upon arrival. (b)(4). Your firm further stated that they (b)(4). This target achievement was cited as the reason for not taking further action.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\n\nAdditionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\n\n5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\n\nDuring the inspection, your firm was asked whether the (b)(4) for the NeoZoline ventilation tubes was validated (b)(4). Your firm stated you have no knowledge or documentation regarding whether the (b)(4) for the NeoZoline Ventilation Tubes had been properly validated. (b)(4) Adept Medical learned the (b)(4) Adept Medical received (b)(4) units of NeoZoline Ventilation Tubes in various types from (b)(4) between June 2023 and November 2023. They released (b)(4) units ((b)(4) boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were (b)(4). Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\n\nThe post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by (b)(4) indicated no adverse events.\n\n(b)(4)\n\nPost market surveillance data indicated we have had no product safety or performance complaints since product launch.\n\nHowever, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier (b)(4) the NeoZoline Ventilation Tube (b)(4) did not have any documentation that the (b)(4) device was validated.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\n\nOur inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\n\nSpecifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a (b)(4) which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if (b)(4). Any (b)(4) may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the (b)(4) to ensure that it can be properly sterilized without (b)(4) becoming unsafe. The change in (b)(4) may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the (b)(4) modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\n(b)(4), Registrar Corp.,\n\n144 Research Drive,\n\nHampton, Virginia,\n\nUSA 23666\n\nPhone: Tel: 1-757-224-0177, Ext. (b)(4)\n\nEmail:(b)(4)@registrarcorp.com","Adept Medical Ltd.","adept-medical-ltd-692226-10112024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024","2026-10-26T08:07:50.120298+00:00","2024-11-26","692226","Mr. Murray Fenton","2026-08-19T17:57:49.713+00:00","2024-10-11",{"id":339,"raw":340,"subject":326,"body_html":344,"body_text":345,"firm_name":346,"letter_id":347,"created_at":348,"fei_number":19,"letter_url":349,"updated_at":350,"action_type":22,"case_status":23,"posted_date":351,"marcs_cms_no":352,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":353,"body_fetched_at":354,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":355,"medical_device_id":19,"response_letter_date":19},1862,[341,342,343,11,326,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:20:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023\">BYD Precision Manufacture Co., Ltd\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liu Xiaoling\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BYD Precision Manufacture Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Baolong Industrial, No. 3001 Baohe Road; Longgangjiedao\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longgang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 5, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Liu Xiaoling:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Shen Haigen, R&amp;D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Process Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic cutting machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic-stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated metal nose piece attachment machines,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> - semi-automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\u003C\u002Fli>\n\t\u003Cli>Your firm provided IQ\u002FOQ\u002FPQ reports for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (equipment number: 40002059), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001993), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001169), belt cutting machine (40002176), \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>machine (40001971), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Device Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “\u003Cem>improve the missing content of the program file\u003C\u002Fem>.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\u003C\u002Fp>\n\n\u003Cp>1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\u003C\u002Fp>\n\n\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\n\n\u003Cp>3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\u003Cbr>\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\u003Cbr>\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\n\n\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\nb. Information that was evaluated to determine if an event was reportable.\u003Cbr>\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Additionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical and Infection Control\u003Cbr>\nDevices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nLisa Van\u003Cbr>\nNova Clinical Solutions\u003Cbr>\n4455 Eastgate Mall, Suite 200\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiu Xiaoling\n\nRecipient Title\n\nGeneral Manager\n\nBYD Precision Manufacture Co., Ltd\n\nBaolong Industrial, No. 3001 Baohe Road; Longgangjiedao\n\nLonggang Qu\n\nShenzhen Shi\n\nGuangdong Sheng, 518116\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 5, 2023\n\nDear Liu Xiaoling:\n\nDuring an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Shen Haigen, R&D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\n\nFor example:\n\nYour firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\n\n2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\n\nFor example:\n\nProcess Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: (b)(4) - automated elastic cutting machines, (b)(4) - automated elastic-stapler machines, (b)(4) - automated stapler machines, (b)(4) - automated metal nose piece attachment machines, (b)(4) - semi-automated stapler machines, (b)(4) individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\n\nYour firm provided IQ\u002FOQ\u002FPQ reports for the (b)(4) semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the (b)(4) machine (equipment number: 40002059), (b)(4) machine (40001993), (b)(4) machine (40001169), belt cutting machine (40002176), (b)(4) machine (40001971), and (b)(4) machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\n\n3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\n\nFor example:\n\nDevice Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\n\n4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\n\nFor example:\n\nYour firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “improve the missing content of the program file.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nFor example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\n\n1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\n\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\n\n3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\n\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\n4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nAdditionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\n\nThe adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\n\nDirector\n\nOHT4: Office of Surgical and Infection Control\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nLisa Van\n\nNova Clinical Solutions\n\n4455 Eastgate Mall, Suite 200\n\nSan Diego, CA 92121","BYD Precision Manufacture Co., Ltd","byd-precision-manufacture-co-ltd-666250-09052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023","2026-10-26T08:08:09.787753+00:00","2023-09-12","666250","Liu Xiaoling","2026-08-20T00:41:41.972+00:00","2023-09-05",{"id":357,"raw":358,"subject":362,"body_html":363,"body_text":364,"firm_name":365,"letter_id":366,"created_at":121,"fei_number":19,"letter_url":367,"updated_at":368,"action_type":22,"case_status":23,"posted_date":369,"marcs_cms_no":370,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":371,"body_fetched_at":372,"delivery_method":90,"recipient_title":19,"reference_number":19,"action_taken_date":373,"medical_device_id":19,"response_letter_date":19},572,[359,360,361,11,362,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finsung-medical-co-ltd-712545-09232025\">Insung Medical Co. Ltd.\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. In-Keum Song\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer (CEO) \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Insung Medical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>168 Gieopdosi-Ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jijeong-Myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wonju-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gangwon-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>26354\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:insungmedical@daum.net\"> insungmedical@daum.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 23, 2025\u003C\u002Fp>\u003Cp>Dear Mr. In-Keum Song:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Gangwon, Korea from April 28, 2025, through May 1, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ANKOR Endobronchial Tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that your firm’s ANKOR Endobronchial Tubes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>The information included for Complaint ISQC‐22‐0513‐02 reasonably suggests that your firm’s ANKOR Endobronchial Tube malfunctioned (i.e. failure of carinal cuff to inflate) during the pre‐use check. Generally, a malfunction is reportable if, among other factors, the malfunction involves a device that is considered to be life‐supporting or life‐sustaining and thus is essential to maintaining human life. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995). The fact that the malfunction occurred once leads to the presumption that the malfunction will recur. Your firm became aware of the referenced event on May 9, 2022. However, based on our records, the FDA has not received a corresponding malfunction report for the referenced event.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2025, and June 30, 2025, did not address the deficiency as it was not included on the FDA Form 483.\u003C\u002Fp>\u003Cp>2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm presented a document “Medical Device Reporting Procedure (MDR)”, Document No.: MDR‐001~MDR‐003, Rev. 0, dated 2025‐01‐08, as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The procedure does not include the definitions for terms outlined at 21 CFR 803.3, including “become aware,” “caused or contributed,” “malfunction,” and “serious injury,\" and the definition for the term “reasonably suggests” found in 803.20(c)(1), which may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>2) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\u003C\u002Fp>\u003Cp>Specifically, your procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for how to complete the FDA 3500A form.\u003C\u002Fp>\u003Cp>b. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\u003C\u002Fp>\u003Cp>c. The circumstances under which your firm must submit supplement or follow-up report required under 21 CFR 803.56 and the requirements for such reports. Without such procedural instructions, your firm might fail to determine when supplemental reports are necessary, provide complete information, or comply with applicable reporting timeframes.\u003C\u002Fp>\u003Cp>Furthermore, it is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of July 2, 2025, your firm does not have such an account. Information about the ESG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2025, and June 30, 2025, did not address the procedural deficiencies as these were not included on the FDA Form 483.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Mr. Bradley Quinn at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS Case #712545, when replying. If you have any questions about the contents of this letter, please contact: Ms. Kimberly Miles at Kimberly.miles@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Kesia Alexander, Ph.D. Director&nbsp;\u003Cbr>OHT 1 Office of Office of Ophthalmic, Anesthesia,\u003Cbr>Respiratory, ENT and Dental Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. In-Keum Song\n\nRecipient Title\n\nPresident & Chief Executive Officer (CEO)\n\nInsung Medical Co. Ltd.\n\n168 Gieopdosi-Ro\n\nJijeong-Myeon\n\nWonju-si\n\nGangwon-do\n\n26354\n\nSouth Korea\n\ninsungmedical@daum.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nSeptember 23, 2025\nDear Mr. In-Keum Song:\nDuring an inspection of your firm located in Gangwon, Korea from April 28, 2025, through May 1, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ANKOR Endobronchial Tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection revealed that your firm’s ANKOR Endobronchial Tubes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\n1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nThe information included for Complaint ISQC‐22‐0513‐02 reasonably suggests that your firm’s ANKOR Endobronchial Tube malfunctioned (i.e. failure of carinal cuff to inflate) during the pre‐use check. Generally, a malfunction is reportable if, among other factors, the malfunction involves a device that is considered to be life‐supporting or life‐sustaining and thus is essential to maintaining human life. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995). The fact that the malfunction occurred once leads to the presumption that the malfunction will recur. Your firm became aware of the referenced event on May 9, 2022. However, based on our records, the FDA has not received a corresponding malfunction report for the referenced event.\nYour firm’s responses dated May 19, 2025, and June 30, 2025, did not address the deficiency as it was not included on the FDA Form 483.\n2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm presented a document “Medical Device Reporting Procedure (MDR)”, Document No.: MDR‐001~MDR‐003, Rev. 0, dated 2025‐01‐08, as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n1) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The procedure does not include the definitions for terms outlined at 21 CFR 803.3, including “become aware,” “caused or contributed,” “malfunction,” and “serious injury,\" and the definition for the term “reasonably suggests” found in 803.20(c)(1), which may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n2) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\nSpecifically, your procedure does not include:\na. Instructions for how to complete the FDA 3500A form.\nb. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\nc. The circumstances under which your firm must submit supplement or follow-up report required under 21 CFR 803.56 and the requirements for such reports. Without such procedural instructions, your firm might fail to determine when supplemental reports are necessary, provide complete information, or comply with applicable reporting timeframes.\nFurthermore, it is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of July 2, 2025, your firm does not have such an account. Information about the ESG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program.\nYour firm’s responses dated May 19, 2025, and June 30, 2025, did not address the procedural deficiencies as these were not included on the FDA Form 483.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Mr. Bradley Quinn at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS Case #712545, when replying. If you have any questions about the contents of this letter, please contact: Ms. Kimberly Miles at Kimberly.miles@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nKesia Alexander, Ph.D. Director\nOHT 1 Office of Office of Ophthalmic, Anesthesia,\nRespiratory, ENT and Dental Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Insung Medical Co. Ltd.","insung-medical-co-ltd-712545-09232025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finsung-medical-co-ltd-712545-09232025","2026-10-26T08:08:59.379658+00:00","2025-09-30","712545","Mr. In-Keum Song","2026-08-19T16:16:19.759+00:00","2025-09-23",{"id":375,"raw":376,"subject":381,"body_html":382,"body_text":383,"firm_name":384,"letter_id":385,"created_at":121,"fei_number":19,"letter_url":386,"updated_at":387,"action_type":22,"case_status":23,"posted_date":388,"marcs_cms_no":389,"product_type":240,"closeout_date":19,"issuing_office":229,"recipient_name":390,"body_fetched_at":391,"delivery_method":392,"recipient_title":19,"reference_number":393,"action_taken_date":394,"medical_device_id":19,"response_letter_date":19},630,[377,378,379,229,380,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-04T04:00:00Z\">09\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuvida-medical-llc-707745-09042025\">NuVida Medical LLC\u003C\u002Fa>","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-707745\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Park Thomas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NuVida Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5814 S 25th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:park.thomas@nuvidamed.com\"> park.thomas@nuvidamed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 04, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-707745\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Thomas:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between February 10, 2025, and February 19, 2025. During the inspection, FDA documented that your company distributes two products derived from human amniotic membrane, Procenta and XCELLERATE; a product consisting of three layers of the placental membrane including amnion (amniotic membrane), chorion (chorionic membrane), and the intermediate layer, completeFT\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>; and a product derived from human dermal tissue, Coll-E-Derm, for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website https:\u002F\u002Fnuvidamed.com\u002F and the website https:\u002F\u002Fextremitycare.com\u002F linked to your website for more information about your products (last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>Procenta, XCELLERATE, and completeFT are each described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a placental tissue allograft that may be used as a protective barrier in wound care applications. The natural properties of amniotic tissue provide mechanical protection and growth factors to support the management of acute and chronic wounds.”\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fli>\u003Cli>Coll-e-Derm is described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a prehydrated human acellular dermal matrix that retains angiogenin and collagen type IV. Angiogenin and collagen type IV may play a key role in supporting revascularization.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Nuvida Medical LLC does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). In the donor, amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) serve as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero. The labeling, advertising, and other indications of your objective intent demonstrate that Procenta, XCELLERATE, and completeFT are intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Procenta, XCELLERATE, and completeFT products are intended for certain wound care applications, including by providing growth factors,\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> that fall outside of the basic function of amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) in the donor. Therefore, Procenta, XCELLERATE, and completeFT fail to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\u003C\u002Fp>\u003Cp>With respect to your Coll-e-Derm™ product, skin in the donor serves to provide covering, protecting the body from external force, and serving as a water-resistant barrier to pathogens or other damaging agents in the external environment. The labeling, advertising, and other indications of your objective intent demonstrate that your Coll-e-Derm™ product is intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Coll-e-Derm™product is intended for use in “supporting revascularization.” Supporting revascularization is not a basic function of dermal tissue in the donor. Supporting revascularization would require biochemical stimulation of a wound healing response in the body via cell signaling, which is not a basic function of dermal tissue in the donor. Therefore, your Coll-e-Derm™ product fails to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated March 12, 2025, to FDA’s Form FDA-483 in detail. We acknowledge your representation that you have corrected the deficiencies documented on the FDA-483. We also acknowledge that you removed certain claims regarding your products from your website based on discussions with the FDA investigator concerning the intended uses of your products. Your voluntary corrections were not sufficient to correct the violations noted in this letter, because your products continue to be intended for non-homologous uses.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding your products and is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003Cbr>\u003Cbr>Cc:&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Oliver Burckhardt\u003Cbr>Chief Operating Officer and Owner\u003Cbr>Extremity Care LLC\u003Cbr>555 E North Ln\u003Cbr>Ste 5000, Bldg D\u003Cbr>Conshohocken, PA 19428\u003C\u002Fp>\u003Cp>Leonard R. Duford\u003Cbr>President and Chief Executive Officer\u003Cbr>Lucina BioSciences, LLC\u003Cbr>14707 E 2nd Ave GL150\u003Cbr>Aurora, CO 80011\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You also market completeFT as an “collagenous amnion\u002Fchorion memrane allograft...derived from placental tissue” and a “full thickness amniotic membrane.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Your product provides growth factors but it is unclear how growth factors would support wound management (such as covering\u002Fprotecting the wound or providing a moist wound environment) as opposed to wound healing.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As stated above, it is unclear how the growth factors in your products would support wound management as opposed to wound healing. Wound healing is not a basic function of amniotic membrane or placental membrane comprising all three layers (amnion, intermediate layer, and chorion).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-707745\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nPark Thomas\n\nRecipient Title\n\nChief Executive Officer and Owner\n\nNuVida Medical LLC\n\n5814 S 25th St\n\nPhoenix, AZ 85040\n\nUnited States\n\npark.thomas@nuvidamed.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 04, 2025\nCBER 25-707745\nDear Mr. Thomas:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between February 10, 2025, and February 19, 2025. During the inspection, FDA documented that your company distributes two products derived from human amniotic membrane, Procenta and XCELLERATE; a product consisting of three layers of the placental membrane including amnion (amniotic membrane), chorion (chorionic membrane), and the intermediate layer, completeFT1; and a product derived from human dermal tissue, Coll-E-Derm, for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website https:\u002F\u002Fnuvidamed.com\u002F and the website https:\u002F\u002Fextremitycare.com\u002F linked to your website for more information about your products (last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nProcenta, XCELLERATE, and completeFT are each described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a placental tissue allograft that may be used as a protective barrier in wound care applications. The natural properties of amniotic tissue provide mechanical protection and growth factors to support the management of acute and chronic wounds.”2\nColl-e-Derm is described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a prehydrated human acellular dermal matrix that retains angiogenin and collagen type IV. Angiogenin and collagen type IV may play a key role in supporting revascularization.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Procenta, XCELLERATE, completeFT, and Coll-e-Derm products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Nuvida Medical LLC does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). In the donor, amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) serve as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero. The labeling, advertising, and other indications of your objective intent demonstrate that Procenta, XCELLERATE, and completeFT are intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Procenta, XCELLERATE, and completeFT products are intended for certain wound care applications, including by providing growth factors,3 that fall outside of the basic function of amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) in the donor. Therefore, Procenta, XCELLERATE, and completeFT fail to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\nWith respect to your Coll-e-Derm™ product, skin in the donor serves to provide covering, protecting the body from external force, and serving as a water-resistant barrier to pathogens or other damaging agents in the external environment. The labeling, advertising, and other indications of your objective intent demonstrate that your Coll-e-Derm™ product is intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Coll-e-Derm™product is intended for use in “supporting revascularization.” Supporting revascularization is not a basic function of dermal tissue in the donor. Supporting revascularization would require biochemical stimulation of a wound healing response in the body via cell signaling, which is not a basic function of dermal tissue in the donor. Therefore, your Coll-e-Derm™ product fails to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.4 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nResponse to the Form FDA-483\nWe have reviewed your response, dated March 12, 2025, to FDA’s Form FDA-483 in detail. We acknowledge your representation that you have corrected the deficiencies documented on the FDA-483. We also acknowledge that you removed certain claims regarding your products from your website based on discussions with the FDA investigator concerning the intended uses of your products. Your voluntary corrections were not sufficient to correct the violations noted in this letter, because your products continue to be intended for non-homologous uses.\nConclusion\nThis letter addresses certain issues regarding your products and is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\nCc:\n(b)(4)\nOliver Burckhardt\nChief Operating Officer and Owner\nExtremity Care LLC\n555 E North Ln\nSte 5000, Bldg D\nConshohocken, PA 19428\nLeonard R. Duford\nPresident and Chief Executive Officer\nLucina BioSciences, LLC\n14707 E 2nd Ave GL150\nAurora, CO 80011\n_______________________________\n1 You also market completeFT as an “collagenous amnion\u002Fchorion memrane allograft...derived from placental tissue” and a “full thickness amniotic membrane.”\n2 Your product provides growth factors but it is unclear how growth factors would support wound management (such as covering\u002Fprotecting the wound or providing a moist wound environment) as opposed to wound healing.\n3 As stated above, it is unclear how the growth factors in your products would support wound management as opposed to wound healing. Wound healing is not a basic function of amniotic membrane or placental membrane comprising all three layers (amnion, intermediate layer, and chorion).\n4 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","NuVida Medical LLC","nuvida-medical-llc-707745-09042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuvida-medical-llc-707745-09042025","2026-10-26T08:09:36.196341+00:00","2025-09-16","707745","Park Thomas","2026-08-19T16:24:00.321+00:00","Via UPS and EMAIL","CBER 25-707745","2025-09-04",35,{"510k":397,"classification":398,"enforcement":399,"event":400,"event_backfill":401,"pma":402,"warning_letter":403},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]